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Se non puoi essere un pino sul monte, 
sii una saggina nella valle, 
ma sii la migliore piccola saggina 
sulla sponda del ruscello. 
Se non puoi essere un albero, 
sii un cespuglio. 
Se non puoi essere una via maestra 
sii un sentiero. 
Se non puoi essere il sole, 
sii una stella. 
Sii sempre il meglio 
di ciò che sei. 
Cerca di scoprire il disegno 
che sei chiamato ad essere, 
poi mettiti a realizzarlo nella vita. 
 
Martin Luther King 
 
 
 
 
 
 
 
 
3 
 
INDEX 
 
 
ABSTRACT 6 
INTRODUCTION 7 
1 Rhabdomyosarcoma 7 
1.1
1.2
1.3
1.4
1.5
1.6 
Soft tissue sarcoma 
Rhabdomyosarcoma: epidemiology and clinical features  
Histogenesis and histologic classification 
Genetic alterations in rhabdomyosarcoma  
Diagnosis and staging 
Treatment of rhabdomyosarcoma 
7 
8 
9 
10 
14 
17 
2 Epigenetics 19 
2.1
2.2
2.3
2.4 
DNA methylation  
DNMTs and tumorigenesis  
Epigenetics in clinical use  
Epigenetics and RMS 
19 
23 
25 
27 
AIM 28 
MATERIALS AND METHODS 29 
Patients clinical features 
Cell lines and cultures 
Transient transfection and RNA interference 
Radiation exposure 
29 
30 
31 
31 
4 
 
RNA isolation 
Reverse transcription and quantitative real time PCR (Q-PCR) 
Cell proliferation assay 
Morphological assessment of siRNA-transfected cells 
Cell cycle analysis  
Apoptosis analysis 
Trans-well migration assay 
Colony formation assay 
U0126 treatment 
Protein extracts and western blot analysis 
Immunofluorescence 
Statistical analysis 
32 
32 
34 
35 
35 
36 
36 
36 
37 
37 
38 
39 
RESULTS 
40 
Expression of DNMT1, DNMT3A and DNMT3B in RMS tumours and cell lines 
siRNA transfection down-regulates DNMT3B expression and inhibits RMS cell 
proliferation 
Decreased DNMT3B expression induces G1 cell cycle arrest 
DNMT3B involvement in apoptosis and migration of RMS cells 
DNMT3B knock-down promotes myogenic differentiation in RMS cells 
MEK/ERK inhibitor U0126 down-regulates DNMT3B protein expression 
Down-regulation of miR-29a/c contributes to altered expression of DNMT3B in 
RMS cells 
Depletion of DNMT3B in alveolar RMS cell line does not have effects on 
proliferation and differentiation 
40 
 
42 
45 
48 
50 
54 
 
56 
 
61 
5 
 
Loss of DNMT3A expression does not alter RMS cells phenotype 
DNMT3B knock-down sensitizes ERMS cell line to radiation 
64 
67 
 
DISCUSSION 71  
REFERENCES 78  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
ABSTRACT 
 
 
Aberrant DNA methylation has been frequently observed in human cancers, including 
rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, representing 
approximately 5% of malignant solid tumour in the paediatric population. However, the 
specific mechanisms and targets are still poorly understood. We showed the up-regulation 
of DNA methyltransferase (DNMT) family members in 14 RMS primary tumour biopsies 
and 4 RMS cell lines in comparison to normal skeletal muscle (NSM). Our study focused 
on DNMT3B gene, which exhibited particularly high levels in RMS samples, in order to 
establish its individual role in this malignancy. RNA interference-mediated DNMT3B 
knock-down decreased cell proliferation, by arresting cell cycle at G1 phase, as 
demonstrated by the reduced expression of Cyclin B1, Cyclin D1 and Cyclin E2, and by 
the concomitant up-regulation of the p21 and p27 checkpoint regulators. DNMT3B 
depleted cells also showed a decreased migratory capacity and clonogenic potential in 
comparison to mocked controls. Interestingly, DNMT3B silencing was able to reactivate 
the skeletal muscle differentiation program in embryonal RMS (ERMS) cells, as confirmed 
by the acquisition of a myogenic-like phenotype and by the increased expression of the 
myogenic markers MYOD1, Myogenin and MyHC. Inhibition of MEK/ERK signalling by 
U0126 resulted in a reduction of DNMT3B protein, leading to cell cycle arrest and 
myogenic terminal differentiation, this supporting the methyltransferase as a down-stream 
molecule of the MEK/ERK oncogenic pathway. Moreover, we showed that DNMT3B is a 
target of specific miR-29 family members in RMS cells and that the restoration of miRNA 
expression levels, by miRNA mimic transfection, lead to decreased cell proliferation and 
migration and to G1 cell cycle arrest. Finally, DNMT3B silencing radiosensitizes ERMS 
cells by altering DNA damage response signalling. Taken together, our data shed further 
light on RMS development, underlying a pivotal role of DNMT3B gene in myogenic 
program. Epigenetic therapy, by targeting the DNA methylation machinery, may represent 
a novel and promising strategy against RMS tumour able to ameliorate traditional therapies 
in order to improve the survival rate for patients with this soft tissue sarcoma.  
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INTRODUCTION 
 
 
1 Rhabdomyosarcoma 
 
 
1.1 Soft tissue sarcoma 
Soft tissue sarcomas are a heterogeneous group of rare tumours that arise predominantly 
from the embryonic mesoderm and start in soft tissues of the body, including muscle, 
tendons, fat, lymph vessels, blood vessels, nerves, and tissue around joints (Cormier and 
Pollock, 2004). Tumours can be found anywhere but mainly originate in an extremity 
(59%), the trunk (19%), the retroperitoneum (15%), or the head and neck (9%) (DeVita et 
al., 2005). Currently, more than 50 subtypes of soft tissue sarcoma have been identified. 
However, soft tissue sarcomas share many clinical and pathologic features: widespread 
infiltration into surrounding tissues, local recurrence, frequent hematogenous 
dissemination (Hartmann and Bauer, 2006). The most common site of metastasis is the 
lung, whilst lymph node metastasis is rare (less than 5%), except for a few histologic 
subtypes such as epithelioid sarcoma, synovial sarcoma, rhabdomyosarcoma, clear-cell 
sarcoma, and angiosarcoma (Fong et al., 1993). 
Although most of soft tissue sarcoma is sporadic, i.e. not associated with hereditary 
syndromes, a small proportion of cases is linked to congenital anomalies or is associated 
with particular genetic disorders such as Beckwith-Wiedemann, Li-Fraumeni, tuberous 
sclerosis, neurofibromatosis type I and Gardner syndrome (Goldblum et al., 2013; Smith et 
al., 2001; Trahair et al., 2007; Yang et al., 1995). Furthermore, external radiation therapy is 
a well-established risk factor for soft tissue sarcoma development (Brady et al., 1992; 
Zahm and Fraumeni, 1997). 
In patients with localized high-risk soft tissue sarcoma, the five-year survival rate is less 
than 50%, whilst is about 10% in patients with metastatic tumour (Lawrence et al., 1987). 
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1.2 Rhabdomyosarcoma: epidemiology and clinical features 
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children (more than 
60%) and is one of the 10 most common childhood malignancies, counting for about 5% of 
paediatric tumours (Parham and Barr, 2013) 
A bimodal age distribution was observed for RMS, including a larger peak between ages 0-
5 years and a smaller peak in adolescence (11-15 years) (A.I.E.O.P.). Males have a 
moderately higher incidence of RMS than females, with a rate ratio of 1.4:1 (M Fatih Okcu 
et al., 2016).  
RMS can occur almost anywhere in the body, but the common primary sites are: head and 
neck (32%), genitourinary tract (bladder/prostate 11%), genitourinary tract non-
bladder/prostate (male 12%, female 5%) and limbs (16%) (McDowell, 2003) (Figure 1). 
 
 
Figure 1: Distribution of rhabdomyosarcoma by primary site. (McDowell, 2003). 
 
About 20-30% of the cases reveal metastasis already at diagnosis; the most frequently 
affected sites are: lung, lymph node, bones and bone marrow (Raney et al., 1988).  
The role of genetic factors in the development of RMS has been confirmed by several 
recent epidemiological observations and in molecular genetic advances.  
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1.3 Histogenesis and histologic classification 
RMS originates from myogenic precursors which have lost control of cell growth and 
differentiation (Merlino and Helman, 1999; Tiffin et al., 2003). Rubin et al. observed that 
rhabdomyosarcoma develops from all subpopulations of muscle cells, including muscle 
satellite cells and differentiating myoblasts (Rubin et al., 2011) (Figure 2). 
 
 
Figure 2: Rhabdomyosarcoma histogenesis. (Rubin et al., 2011). 
 
Skeletal muscles are formed from the paraxial mesoderm surrounding the neural tube. 
Cells of the dermomyotome develop into skeletal muscles of the trunk and limbs. Pax3 is 
involved in the induction and migration of myoblast precursors, by directly modulating the 
levels of the c-Met tyrosine kinase receptor (Epstein et al., 1996; Relaix et al., 2003) and 
the expression of the muscle-specific transcription factors, MYOD, Myf-5 and Myogenin. 
When muscle tissues begin to differentiate, and the myogenic transcription factors are 
activated, Pax3 gene is down-regulated (Bailey et al., 2001; Lamey et al., 2004). In muscle 
tumours, Pax3 ectopic expression is observed, this resulting in a significant c-Met up-
regulation (Chen et al., 2007).  
Although RMS has been described for the first time in 1854, histologic subtypes have been 
defined many years later. In 1958, Horn and Enterline proposed that RMS could be 
classified into embryonal, alveolar, botryoid, and pleomorphic types (Horn & Enterline, 
1958). 
Embryonal rhabdomyosarcomas (ERMS), the most common subtype, comprise a range of 
histological features that encompass variable degrees of embryonic rhabdomyogenesis. A 
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common theme is a variably “loose and dense” cellularity within a myxoid matrix. ERMS 
arises in infants and young children and often involve head, neck, and the urogenital tract. 
Alveolar rhabdomyosarcomas (ARMS) resemble fetal lung alveoli with malignant cells 
that form aggregates interrupted by fibrovascular septa and areas of discohesion. ARMS 
tumour most commonly occurs in adolescents and arises in extremities and parameningeal 
locations. Botryoid rhabdomyosarcoma (BRMS), also called as “sarcoma botryoides,” 
forms grape-like polypoid masses partially lined by epithelium and shows heightened 
subepithelial cellularity. BRMS, by definition, occurs in hollow viscera, usually in young 
children. 
Finally, pleomorphic rhabdomyosarcoma (PRMS) contains intersecting bundles of large, 
variably myogenic spindle cells with hyperchromatic, irregular nuclei and prominent 
nucleoli; the spindle cells are often arranged in storiform whorls resembling “malignant 
fibrous histiocytoma”. PRMS arises from the skeletal muscle of the extremities and mainly 
occurs in adults. 
The classification proposed by the Intergroup Rhabdomyosarcoma Study Group (IRSG) 
subdivides the histotypes into four prognostic groups: ARMS and undifferentiated sarcoma 
are associated with unfavorable prognosis, BRMS is associated with favorable prognosis, 
ERMS with intermediate prognosis and finally RMS with rabdoid features is associated 
with uncertain prognosis (Newton et al., 1988). 
The five-year survival rate is about 73% for patients with ERMS and 48% for patients with 
ARMS (Ognjanovic et al., 2009). ARMS subtype often shows metastasis already at 
diagnosis and is characterised by a more aggressive growth compared to the ERMS 
subtype, with poor response to therapy and worse prognosis (Breneman et al., 2003). 
 
 
1.4 Genetic alterations in rhabdomyosarcoma 
Cytogenetic and molecular analysis have identified chromosomal abnormalities in all the 
RMS subtypes, however, karyotypic studies revealed nonrandom chromosomal 
translocations that distinguish ARMS from ERMS and other solid tumours (Parham and 
Barr, 2013). The most common chromosomal translocation in ARMS is t(2;13)(q35;q14), 
which involves the long arm of chromosome 13 and the long arm of chromosome 2 
(Douglass et al., 1987; Wang-Wuu et al., 1988), and more rarely is present the 
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translocation t(1;13)(p36;q14), which involves the long arm of chromosome 13 and the 
short arm of chromosome 1 (Biegel et al., 1991; Douglass et al., 1991) (Figure 3).  
 
 
Figure 3: Schematic representation of the chromosomal translocations involving PAX3/PAX7 
and FKHR. (Wang et al., 2008). 
 
The involved genes on chromosomes 2 and 1 are PAX3 and PAX7, respectively, which 
encode highly related members of the paired box family of transcription factors (Barr et al., 
1993; Lovell et al., 1994). These genes are characterised by three highly conserved 
domains: the paired box domain (PD), the octapeptide (OP) and the homeobox domain 
(HD) (Figure 4A). The temporal and spatial expressions of these highly conserved genes 
are tightly regulated during fetal development including organogenesis (Wang et al., 
2008b). The fusion partner on chromosome 13 is FOXO1 (also known as FKHR), which 
encodes a member of the forkhead family of transcription factors encompassing a forkhead 
preserved domain (FH) (Galili et al., 1993; Lovell et al., 1994) (Figure 4A). The fusion 
genes generated by t(2;13)(q35;q14) and t(1;13)(p36;q14) translocations are expressed as 
fusion transcripts and translated into PAX3-FOXO1 and PAX7-FOXO1 fusion proteins, 
which respectively contain the PAX3 or PAX7 DNA-binding domain and the FOXO1 
transcriptional activation domain (TAD) (Parham and Barr, 2013) (Figure 4B). These 
fusion proteins activate transcription from PAX3/PAX7-binding sites but are more potent 
(10-100 times) as transcriptional activators than the wild-type PAX3 and PAX7 proteins 
(Bennicelli et al., 1996, 1999). 
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Figure 4: Gene translocations in alveolar rhabdomyosarcoma. A Wild-type proteins and the 
resulting B fusion proteins arising from chromosomal translocations occurring in ARMS. (Adapted 
from Kashi et al., 2015). 
 
In addition to functional changes, the PAX3-FOXO1 and PAX7-FOXO1 fusion products 
are expressed at higher levels than the corresponding wild-type proteins (Davis and Barr, 
1997). During normal development, PAX3 expression occurs in the dermomyotome and it 
is required for the normal migration of skeletal muscle precursors to the limb bud (Daston 
et al., 1996). PAX7 expression is a marker of satellite cells in adult skeletal muscle 
(SEALE, 2000) and it is required for normal self-renewal (Oustanina et al., 2004). These 
changes result in high expression of potent transcription factors that contribute to 
tumorigenesis by altering growth and apoptotic pathways, modulating myogenic 
differentiation, and stimulating motility and other metastatic pathways (Barr, 2001). Barr et 
al. (Barr et al., 1996) showed that PAX3-FOXO1 is a more potent oncogene than PAX7-
FOXO1, since genomic amplification of PAX7-FOXO1 is required for tumorigenesis, 
whilst a single copy of PAX3-FOXO1 is sufficient. 
Comparison between fusion-negative and fusion-positive tumours has highlighted that the 
failure-free survival is worst in ARMS patients carrying PAX3/7-FOXO1 translocations 
(Skapek et al., 2013). 
In ERMS tumours, the most common chromosomal aberration is loss of heterozygosity 
(LOH) of the short arm of chromosome 11 (11p15.5) (Koufos et al., 1985; Scrable et al., 
1987), this leading to over-expression of the insulin-like growth factor II (IGF-II) (Minniti 
et al., 1994; Xia et al., 2002). Other paediatric tumours also show loss of heterozygosity or 
loss of imprinting (LOI) in this region, which is associated with the Beckwith-Wiedemann 
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syndrome (O’Brien et al., 2012). The 11p15.5 region contains numerous tumour 
suppressor genes, such as H19 and p57 (CDKN1C) (Xia et al., 2002), which are 
specifically expressed from the maternal allele and encode for proteins or RNA products 
with cell growth inhibitory activity (Onyango and Feinberg, 2011; Weksberg et al., 2010). 
Analysis of the parental derivation of the two alleles revealed that ERMS tumours 
preferentially maintain the inactive paternal allele and lose the active maternal allele, 
leading to the inactivation of tumour suppressor genes (Scrable et al., 1989) (Figure 5). 
 
 
Figure 5: Allelic loss of imprinted region at 11p15.5 in ERMS. Green indicates an expressed 
allele and red indicates an unexpressed allele. 
 
Several studies described the presence of point mutations in potential oncogenes and 
tumour suppressor genes both in ARMS and ERMS cases (Felix et al., 1992; Gao et al., 
1998; Stratton et al., 1989), with point mutations being more frequent in ERMS than in 
ARMS tumours (Shukla et al., 2012). Mutated genes are members of the RAS family, 
including FGFR4, PIK3CA, CTNNB1, BRAF, p53 and PTPN11. Gene amplification 
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(MYCN, MDM2, GLI, SAS and CDK4) and chromosome duplication (2, 8, 12 and 13) 
have also been described (Anderson et al., 1999; Gordon et al., 2001). 
 
 
1.5 Diagnosis and staging 
The histologic patterns and cytologic features of RMS range from undifferentiated small 
round blue cell neoplasms to lesions with advanced cytohistologic features, reminiscent of 
rhabdomyomas (Kodet et al., 1991). For the RMS diagnosis, it is necessary to identify 
embryonic myogenesis by using diagnostic tests and biopsy that allow to measure 
myogenic markers such as desmin, muscle-specific actin, myosin, or myoglobin. In recent 
years, nuclear transcription factors that initiate myogenesis, such as MYOD or Myogenin, 
have become common immunohistochemical markers, because of their expression 
precedes later events of myogenesis such as the identification of cytoplasmic striations, 
myosin-ribosome complexes, and markers of terminal differentiation like myoglobin and 
muscle-specific actin (Cessna et al., 2001; Folpe, 2002).  
As for other tumours, staging classification is necessary for RMS (1) to classify tumour 
and its severity in order to make the best choice from the different modalities of treatment 
and (2) to compare the results of treatment in different countries. Two systems of staging 
have been used throughout the world. The pre-surgical and post-surgical staging system, 
known as TNM/pTNM, which describes the size of the primary tumour (T), the 
involvement of the regional limph nodes (N) and the presence of distant metastasis (M) 
before any treatment administration (Table 1A, 1B). The post-surgical staging system, 
known as the Intergroup Rhabdomyosarcoma Study (IRS) Grouping System, is based on 
surgery (Table 2) (Panda et al., 2017). In Europe, the most used system is the European 
Paediatric Soft Tissue Sarcoma Study Group (EpSSG) Risk Classification, which considers 
histology (alveolar vs. non-alveolar), post-surgical stage (according to IRS grouping), 
tumour site and size, limph node involvement and patient age (Table 3). 
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Table 1A: TNM classification 
Tumour: 
T0: No evidence of tumour 
T1: Tumour confined to organ or tissue of origin T1a: Tumour ≤ 5 cm in greatest dimension 
 T1b: Tumour > 5 cm in greatest dimension 
T2: Tumour not confined to organ or tissue of origin T2a: Tumour ≤ 5 cm in greatest dimension 
 T2b: Tumour > 5 cm in greatest dimension 
TX: No information on size and tumour invasiveness 
Lymph nodes: 
N0: No evidence of lymph node involvement 
N1: Evidence of regional lymph node involvement 
NX: No information on lymph node involvement 
Metastasis: 
M0: No evidence of metastases or non-regional lymph nodes 
M1: Evidence of distant metastasis or involvement of non-regional lymph nodes 
MX: No information on metastasis 
 
 
Table 1B: pTNM classification 
pT 
pT0: No evidence of tumour found on histological examination of specimen. 
pT1: Tumour limited to organ or tissue of origin.   
         Excision complete and margins histologically free 
pT2: Tumour with invasion beyond the organ or tissue of origin. 
         Excision complete and margins histologically free 
pT3: Tumour with or without invasion beyond the organ or tissue of origin 
         Excision incomplete 
                        pT3a: Evidence of microscopic residual tumour 
                        pT3b: Evidence of macroscopic residual tumour 
                        pT3c: Adjacent malignant effusion regardless of size 
pTX: Tumour status may not be assessed 
pN 
pN0:  No evidence of tumour found on histological examination of regional lymph nodes 
pN1:  Evidence of invasion of regional lymph nodes 
                             pN1a: Evidence of invasion of regional lymph nodes 
                             Involved nodes considered to be completely resected 
                             pN1b: Evidence of invasion of regional lymph nodes 
                             Involved nodes considered not to be completely resected 
pNX:  N status may not be assessed due to lack of pathological examination or inadequate information                               
           on pathological findings 
pM 
pM0:   No evidence of metastasis found on histological examination of non-regional lymph nodes 
pM1:   Evidence of metastasis on histological examination 
pMX:  M status may not be assessed due to lack of pathological examination or inadequate information  
            on pathological findings 
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Table 2: IRS Grouping System 
IRS Group  Definition  
I Tumour macroscopically and microscopically removed 
(IA) Tumour confined to organ or tissue of origin 
(IB) Tumour not confined to organ or tissue of origin 
II Macroscopic complete resection but microscopic residuals 
IIA            Lymph nodes not affected   
IIB            Lymph nodes affected but removed 
 
 
III 
Macroscopic complete resection but microscopic residuals and 
lymph nodes affected and not removed 
Macroscopic residuals after resection or biopsy with malignant 
effusion 
IV Metastasis present or non-regional lymph nodes involved 
 
 
Table 3: EpSSG Risk Classification 
Risk Group Subgroups Pathology 
 
Post-
surgical 
Stage 
(IRS 
Group) 
 
Site 
 
Node 
Stage 
 
Size & Age 
 
Low Risk A Favourable I Any N0 Favourable 
 B Favourable I Any N0 Unfavourable 
Standard 
Risk 
C Favourable II, III Favourable N0 Any 
 D Favourable II, III Unfavourable N0 Favourable 
 E Favourable II, III Unfavourable N0 Unfavourable 
High Risk F Favourable I, II, III Any N1 Any 
 G Unfavourable I, II, III Any N0 Any 
Very High 
Risk 
H Unfavourable I, II, III Any N1 Any 
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1.6 Treatment of rhabdomyosarcoma 
Because local progression and relapses are the main causes of failure, treatment for RMS 
involves a multimodality approach that includes local surgery, radiotherapy and systemic 
chemotherapy (Panda et al., 2017). Surgery should be considered if the tumour can be 
completely excised with histologically clear margins and no anatomical or functional 
impairment (Sultan and Ferrari, 2010). Radiotherapy is a fundamental part in the strategy 
for treating RMS, it is use both pre- and post- surgery (Michalski et al., 2004; Schuck et al., 
2004). Dosage, timing and method of radiotherapy must be planned in relation to the 
patients’ risk stratification and the late effects of treatment (Stevens, 2005). Moreover, it 
should be considered, that radiotherapy has been implicated in the development of 
secondary malignancies (Heyn et al., 1993; Paulino, 2004). Because RMS patients are 
assumed to have micrometastatic disease already at diagnosis, chemotherapy represents the 
gold standard for all the patients (Ferrari and Casanova, 2005; Meyer and Spunt, 2004; 
Parham, 2001; Raney et al., 2001; Ruymann and Grovas, 2000). To date, there are two 
protocols of chemotherapy. In North America the standard is vincristine, actinomycin D, 
and cyclophosphamide (VAC) (Maurer et al., 1988), whilst in Europe the standard is 
represented by ifosfamide, vincristine and actinomycin D (IVA) (Casanova and Ferrari, 
2011; Crist et al., 2001). 
For 30% of RMS cases these approach is still not effective, or not effective enough to 
achieve a definitive cure (Casanova and Ferrari, 2011). In the recent years, targeted 
therapy has been developed as novel and promising molecular strategy that specifically 
target crucial genes of the tumour biology without affecting normal cells (Sultan and 
Ferrari, 2010; Wachtel and Schäfer, 2010). Potential therapeutic targets have been 
identified in RMS. Receptor tyrosine kinases (RTKs) such as IGF1R (Cao et al., 2008; 
Kalebic et al., 1998; Maloney et al., 2003; Tsokos and Helman, 1994), c-MET (Taulli et al., 
2006), PDGFR (Maris et al., 2008a; Taniguchi et al., 2008) and c-KIT (Maris et al., 2008a). 
Intracellular signalling molecules such as mTOR (Hosoi et al., 1999; Houghton et al., 
2008a; Wan et al., 2006) and MEK/ERK (Ciccarelli et al., 2005; Marampon et al., 2006). 
Cell cycle or apoptosis regulators such as CDK4/CDK6 (Saab et al., 2006), p53 (Ganjavi et 
al., 2005; Shetty et al., 2002), BCL-2 (Lock et al., 2008), and TRAIL (Clayer et al., 2001; 
Izeradjene et al., 2004; Komdeur et al., 2004; Petak et al., 2000; Tomek et al., 2003). 
Moreover, proteasome (Bersani et al., 2008; Houghton et al., 2008b), histone deacetylases 
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(Jaboin et al., 2002; Kutko et al., 2003), regulators of angiogenesis such as VEGF (Gee et 
al., 2005) and VEGFR (Maris et al., 2008b) and finally the cancer specific fusion proteins 
PAX3-FOXO1 and PAX7-FOXO1 (Amstutz et al., 2008; Van Den Broeke et al., 2006; 
Dagher et al., 2002; Gardner and Montminy, 2005; Mackall et al., 2008) (Figure 6). 
 
 
Figure 6: Rhabdomyosarcoma pathways for targeted therapy. (Kashi et al., 2015). 
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2 Epigenetics  
The term “epigenetics” literally means “above genetics”, indeed, the Greek prefix epi-
 (ἐπι- “over, outside of, around”) in epigenetics implies features that are “on top of” or “in 
addition to” the traditional genetic basis for inheritance (Laker and Ryall, 2016). Conrad 
Waddington introduced the term “epigenetics” in the early 1940s. He defined epigenetics 
as “the branch of biology which studies the causal interactions between genes and their 
products which bring the phenotype into being” (Waddington, 1942, 1968). The meaning 
of the word has gradually narrowed. Today, epigenetics is defined as “the study of changes 
in gene function that are mitotically and/or meiotically heritable and that do not entail a 
change in DNA sequence” (Wu Ct and Morris, 2001). The most frequent epigenetic 
modifications are histone and/or DNA methylation, generally associated with gene 
silencing, and histone acetylation, related to transcriptional activation (Allfrey et al., 1964; 
Bogdanović and Veenstra, 2009; Esteller, 2008).  
 
 
2.1 DNA methylation 
DNA methylation plays a key role in the regulation of gene expression, genomic 
imprinting, X chromosome inactivation, and tumorigenesis (Jones and Baylin, 2007; Smith 
and Meissner, 2013). In mammals, the addition of a methyl group at the carbon fifth 
position of a cytosine in the context of the cytosine-guanosine (CpG) dinucleotide (Figure 
7) is catalysed by a group of enzymes called DNA methyltransferases (DNMTs) (Hamidi 
et al., 2015).  
 
 
Figure 7: DNA methylation. DNMTs transfer a methyl group at the DNA cytosine ring carbon C5 
by using S-adenosyl methionine (SAM) as methyl donor. S-adenosyl homocysteine (SAH) is the 
cofactor product. (Adapted from Maresca et al., 2015). 
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In the human genome there are 56 million of CG sites, 60–80% of which are methylated, 
corresponding to 4–6% of all cytosines (Laurent et al., 2010). Around 70% of human gene 
promoter regions present CpG islands. Methylation levels and patterns are cell and tissue 
specific. 
The mammalian DNMT family includes four members: DNMT1, DNMT3A, DNMT3B, 
and DNMT3L (Kim et al., 2009; Mohan and Chaillet, 2013). These enzymes share 
conserved motifs in their C-terminal catalytic domains, but have different N-terminal 
regulatory regions (Figure 8) (Jurkowska et al., 2011). N-terminal region is involved in the 
interaction with DNA, chromatin, and other proteins and furthermore contains 621 amino 
acids required for discriminating between hemimethylated and unmethylated DNA 
(Maresca et al., 2015). DNMT1 contains multiple functional domains in the N-terminal 
region:  
- DNA methyltransferase associated protein 1 (DMAP1) involved in the interaction 
of DNMT1 with the transcriptional repressor DMAP1 as well as in the stability of 
the enzyme and in its binding to DNA CpG sites (Ding and Chaillet, 2002; 
Rountree et al., 2000), 
- a nuclear localization signal (NSL), a replication foci-targeting sequence (RFTS) 
that localizes DNMT1 at the centromeric chromatin and to the DNA replication 
fork (Easwaran et al., 2004; Fellinger et al., 2009), 
- a zing finger CXXC domain that specifically recognizes unmethylated CpG-
containing DNA (Pradhan et al., 2008), 
- a pair of bromo-adyacent homology (BAH1, BAH2) domains, 
- a glycine-lysine (GK) repeat that link N-terminal regulatory region to the C-
terminal catalytic domain.  
The N-terminal region of DNMT3A and DNMT3B have two functional domains: a 
proline-tryptophan-tryptophan-proline (PWWP) domain, which is required for 
heterochromatin localization (Chen et al., 2004; Cheng and Blumenthal, 2008; Qiu et 
al., 2002) but not for CpG methylating activity (Qiu et al., 2002), and an ATRX-
DNMT3A/3B-DNMT3L (ADD) domain that binds to H3K4-unmethylated histone H3 
and constitutes a platform for various protein–protein interactions (Otani et al., 2009). 
DNMT3L lacks a PWWP domain but has an ADD domain, which interacts with 
histone H3 when K4 is unmethylated (Ooi et al., 2007). 
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The C-terminal catalytic domain is composed by 500 amino acids and harbors the active 
center of the enzyme, which contains amino acid motifs, called the “AdoMet-dependent 
MTase fold", that are typical of the cytosine-C5 methyltransferases (Jurkowska et al., 
2011). Motifs I and X of this domain are involved in cofactor binding whereas motifs IV, 
VI, and VIII have a catalytic function. The non-conserved region between motifs VIII and 
IX is the target recognition domain (TRD), which is crucial for DNA recognition and 
specificity (Cheng, 1995; Cheng and Blumenthal, 2008; Jeltsch, 2002). DNMT3L lacks the 
DNMTs motifs IX and X and all the important catalytic residues in its C-terminal portion 
(Maresca et al., 2015). 
 
 
Figure 8: A schematic representation of the domain structure in the human DNMT isoforms. 
(Adapted from Maresca et al., 2015). 
 
DNMT1, DNMT3A and DNMT3B have different functions in the methylation process. 
DNMT1 is required for the maintenance of all methylation in the genome. During DNA 
replication, DNMT1 methylates hemimethylated DNA and restores the specific 
methylation pattern from the parental strand on the newly synthesized daughter strand. 
Mice deficient in Dnmt1 exhibit embryonic lethality (Li et al., 1992). Conversely, 
DNMT3A and DNMT3B function as de novo methyltransferases, which establish DNA 
methylation patterns during gametogenesis and early embryogenesis, and set up genomic 
imprints during germ cell development (Chen and Li, 2006; Li and Zhang, 2014). 
Although they are highly expressed in early mammalian embryos, DNMT3A and 
DNMT3B levels decrease during cell differentiation. These two proteins have distinct 
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functions throughout embryonic development, showing both spatial and temporal 
differences. DNMT3A primarily methylates a set of genes and sequences at the late stage 
of embryonic development (mainly after birth), whilst DNMT3B modifies a broader region 
of genomic sequences in early embryos (Li and Zhang, 2014; Smith and Meissner, 2013). 
Knockout of DNMT3A or DNMT3B is lethal, being both essential for embryonic 
development in mice. Mouse embryos with dnmt3b knockout die in utero, whilst animals 
with dnmt3a knockout exhibit postnatal growth retardation and dysplasia, and die shortly 
after birth (Okano et al., 1999). A classical model of DNA methylation is schematized in 
Figure 9. 
 
 
Figure 9: DNA methylation model. De novo and maintenance methylation. (Adapted from Li and 
Zhang, 2014). 
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DNMT3L, an important regulator without catalytic activity, is a co-factor of DNMT3A 
(Chen and Li, 2004; Li and Zhang, 2014; Smith and Meissner, 2013) and is essential for 
the establishment of genomic imprinting in germ cells (Bourc’his et al., 2001). Mice with 
dnmt3l knockout are viable, but male are sterile (Hata et al., 2002). 
The DNMT family also includes DNMT2, which methylates small transfer RNAs (tRNAs) 
(Goll et al., 2006) and is not currently considered to be a DNA methylase. Thus, DNMT2 
seems to have intermediate properties, sharing structural/catalytic features of a DNMT and 
nuclear-cytoplasmic localization of a RNA methyltransferase (Schaefer et al., 2008). 
Moreover, a recent study identified a new de novo DNA methyltransferase, called 
DNMT3C, in murine germ cells. DNMT3C exhibits high identity with DNMT3B, and is 
specialized in methylating the young retrotransposons. Male mice without Dnmt3c are 
sterile (Barau et al., 2016).  
 
 
2.2 DNMTs and tumorigenesis 
An altered pattern of epigenetic modifications is central to many common human diseases, 
including cancer. Deregulation of DNA methylation induces imbalances in DNA 
modification, resulting in chromatin remodelling, genomic instability and gene inactivation 
(Zhang and Xu, 2017). Unlike normal tissue genomes, tumour cell genomes generally 
display global hypomethylation throughout, with localized hypermethylation in particular 
regions (Figure 10) (Dawson and Kouzarides, 2012).  
Low level of DNA methylation was one of the first epigenetic alterations found in human 
cancers in comparison to normal tissues (Feinberg and Vogelstein, 1983). During the 
development of a neoplasm, the degree of DNA hypomethylation increases as the lesion 
progresses, from a benign proliferation of cells to an invasive cancer (Fraga et al., 2004). 
The global DNA hypomethylation in tumour cells results in a reduction of 5-
methylcytosine, generally at gene-coding regions and satellite repeats. These changes 
cause mitotic recombination, leading to deletions and translocations (Eden et al., 2003) and 
even loss of imprinting and reactivation of transposable elements (Esteller, 2008; Zhang 
and Xu, 2017). Two examples of the hypomethylation mechanisms are the activation of 
PAX2 gene, which encodes a transcription factor involved in cell proliferation, as well as 
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the expression of let-7a-3 miRNA gene, which is implicated in colon cancer (Brueckner et 
al., 2007; Wu et al., 2005). 
 
 
Figure 10: Aberrant DNA methylation in tumorigenesis. (Esteller, 2007). 
 
Throughout malignant transformation, localized hypermethylation of several CpG-island 
promoters induces the transcriptional silencing of tumour suppressor genes (TSGs) (Baylin 
and Jones, 2014; Feinberg et al., 2016; Hanahan and Weinberg, 2000). Profiles of 
hypermethylation of the CpG islands in tumour-suppressor genes are specific to cancer 
type (Costello et al., 2000; Esteller et al., 2001a). A defining DNA “hypermethylome” can 
be assigned to each tumour type. These alterations can affect genes involved in the cell 
cycle, DNA repair, carcinogen metabolism, cell-to-cell interaction, apoptosis, and 
angiogenesis, all of which are involved in the development of cancer (Esteller, 2007; 
Herman and Baylin, 2003). Indeed, transcriptional repression of different TSGs, such as 
Rb (Greger et al., 1989; Sakai et al., 1991), p16/CDKN2A (Gonzalez-Zulueta et al., 1995; 
Herman et al., 1995; Merlo et al., 1995), RASSF1, MLH1 (Herman and Baylin, 2003), 
BRCA1 (Butcher and Rodenhiser, 2007; Esteller et al., 2000a; Herman and Baylin, 2003) 
etc., has been extensively described in several malignancies (Shafiei et al., 2008; Zhao et 
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al., 2010). Silencing of the DNA-repair gene blocks the repair of genetic mistakes, thereby 
opening the way to neoplastic transformation of the cell (Esteller, 2008). 
Although deregulation of DNA methylation pattern is attributed to different mechanisms, 
alteration of DNMT1, 3A and 3B is a primary causative factor (Herman et al., 1996; Laird, 
2003). Aberrant quantity/activity of DNMT3 family enzymes may depends on deletion, 
over-expression and mutation, however, the over-expression of DNMTs is the most 
described alteration in several human tumour types, including lymphomas, liver, prostate, 
colorectal, breast, lung, pancreatic and endometrial cancer (Eads et al., 1999; Gao et al., 
2011; Girault et al., 2003; Jin et al., 2005; Patra et al., 2002; Saito et al., 2003), and is 
generally associated with a more aggressive phenotype, indicating that DNMT1, 3A and 
3B likely act as oncogenes (Fernandez et al., 2012). 
 
 
2.3 Epigenetics in clinical use 
The DNA-methylation and histone-modification patterns have potential clinical use. DNA 
hypermethylation markers are under study as complementary diagnostic tools, prognostic 
factors, and predictors of treatment responses (Figure 11) (Esteller, 2008).  
For instance, the glutathione S-transferase gene (GSTP1) is hypermethylated in 80 to 90% 
of patients with prostate cancer (Cairns et al., 2001; Esteller et al., 1998; Lee et al., 1994), 
but it is not hypermethylated in benign hyperplastic prostate tissue (Jerónimo et al., 2001). 
Moreover, because hypermethylation of the CpG island is an early event in the 
development of cancer, identification of DNA hypermethylation in a breast-biopsy 
specimen from a carrier of a BRCA1 mutation could be useful when the pathological 
diagnosis is uncertain (Esteller et al., 2001b), considering that for breast cancer, as for 
other cancers types, early detection is the most efficient strategy to decrease mortality (Lo 
and Sukumar, 2008). The application of DNA hypermethylation as cancer cell markers in 
clinical practice will require rapid, accurate, quantitative and cost-effective techniques as 
well as objective criteria for the selection of genes having a pivotal role in different tumour 
types (Esteller, 2008). 
Epigenomic profiles might be used as biomarkers for tumour prognosis. For example, 
hypermethylation of the death-associated protein kinase (DAPK), p16, and epithelial 
membrane protein 3 (EMP3) has been linked to poor outcomes in lung, colorectal, and 
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brain cancer, respectively (Esteller, 2007). Muller et al. studied 39 genes in serum circulant 
DNA from normal control patients and patients with primary or metastatic breast cancer 
and identified two genes, RASSF1A and APC, whose methylation has a statistically 
significant association with poor outcome (Muller et al., 2003). Prognostic dendograms 
have also been developed. These epigenomic profiles have the advantage that they can be 
assayed using DNA that has been extracted from archived material (Esteller, 2005, 2007; 
Laird, 2003). 
Finally, the hypermethylation of specific genes can potentially be used as a predictor to 
evaluate the chemotherapy response in affected patients. Two studies have shown that the 
hypermethylation of MGMT is an independent predictor of a favourable response of 
gliomas to carmustine (BCNU) (Esteller et al., 2000b) or Temozolomide (Rimel et al., 
2009). Widschwendter et al. showed that the methylation status analysis of the oestrogen 
receptor (ERα) represents an alternative parameter to determine whether endocrine therapy 
will be effective in breast cancer patients (Widschwendter et al., 2004), since 30% of 
breast tumours show promoter hypermethylation of ERα gene (Lapidus et al., 1998; 
Ottaviano et al., 1994) and are resistant to endocrine therapy.  
Because epigenetic alterations are potentially reversible, DNMTs also represent attractive 
therapeutic targets since their inhibition might have the ability to overturn tumour cell 
phenotype (Aldawsari et al., 2015; Erdmann et al., 2015; Subramaniam et al., 2014). DNA-
demethylating drugs in low doses have shown a significant antitumoral activity and US 
Food and Drug Administration (FDA) has approved the use of two such agents, 5-
azacytidine (Vidaza) and 5-aza-2-deoxycytidine (decitabine), as elective treatments for 
myelodisplastic syndrome and leukemia (Mack, 2006; Müller et al., 2006; Oki et al., 
2007).  
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Figure 11: Epigenetics in Cancer Management. (Esteller 2008). 
 
 
2.4 Epigenetics and RMS 
In a previous work Chen et al. have analysed the expression of DNMT1 in 32 RMS and 12 
normal muscle samples showing an increased expression of this gene with a statistically 
significant difference in ARMS and ERMS cases (Chen et al., 1999). Moreover, DNA 
methylation signatures have been recently described in ARMS and ERMS patients, 
suggesting that aberrant DNA methylation may contribute to the development of RMS. 
Furthermore, cluster analysis revealed that embryonal and alveolar subtypes have distinct 
DNA methylation patterns, with ARMSs being enriched in DNA hypermethylation of 
polycomb target genes (Mahoney et al., 2012). Indeed, hypermethylated CpG islands have 
been identified in several genes involved in oncogenesis, skeletal muscle development and 
differentiation in both RMS cell lines and primary tumour samples (Chen et al., 1998; 
Gastaldi et al., 2006; Mahoney et al., 2012). Consistently, treatment with 5-aza-2’-
deoxycytidine (5-aza-dC), a general DNA demethylating agent, is able to suppress 
tumorigenicity and partially reactivate myogenic program in different RMS cell lines 
(Gastaldi et al., 2006; Megiorni et al., 2014). 
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AIM 
 
 
The aim of the present research project was to analyse the expression levels and the 
specific role of the de novo DNA methyltransferase DNMT3A and DNMT3B in RMS 
tumorigenesis. 
In this regard, we examined the transcript levels of these DNMTs in RMS primary tumour 
cases and cell lines and the biological consequences of their inhibition in RMS in vitro 
models. Indeed, we performed RNA-interference experiments to evaluate the effects of 
DNMT3A or DNMT3B silencing on phenotype, cell cycle, apoptosis, migration and ability 
to form colonies of RMS cells. We also investigated the ability of cells depleted of the two 
specific DNMTs to properly reactivate the myogenic differentiation program by 
morphologic analysis, as well as the expression of specific muscle markers. Finally, we 
analysed whether DNMT silencing can potentiate the antitumour effects in RMS of 
standard radiotherapy. 
The results of our project represent a further step towards the comprehension on RMS 
development, which might lead to more efficient and less toxic treatments for RMS 
patients. 
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MATERIALS AND METHODS 
 
 
Patient clinical features 
Fourteen RMS primary tumour samples, 7 ARMSs and 7 ERMSs, were obtained at 
diagnosis before any treatment from children admitted to the Department of Paediatrics 
and Infantile Neuropsychiatry at “Sapienza” University, and the Department of Oncology 
at the Alder Hey Children’s NHS Foundation Trust, Liverpool. Histopathological diagnosis 
was confirmed using immunohistochemistry. All 7 ARMS cases were investigated for 
t(2;13)(q35;q14) or t(1;13)(p36;q14) translocations that involve PAX3/7 genes (mapped on 
chromosome 2 and 1, respectively) and FOXO1 gene (mapped on chromosome 13) by 
using standard FISH (Fluorescent In Situ Hybridization),  analysis: 5 tumours were PAX3-
FOXO1-positive, 1 was PAX7-FOXO1-positive and 1 was fusion-negative. Patients were 
grouped according to the IRS post-surgical Grouping System. Details of the patients are 
described in Table 5.  
Samples were immediately frozen in liquid nitrogen after surgery and stored at -80°C. 
Normal skeletal muscle (NSM), obtained from eight children undergoing surgery for non-
oncological conditions, was used as negative control. Institutional written informed 
consent was obtained from the patient’s parents or legal guardians. The study underwent 
ethical review and approval according to the local institutional guidelines (Alder Hey 
Children’s NHS Foundation Trust Ethics Committee, approval number 09/H1002/88). 
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Table 5: Clinicopathological features of the analysed tumour cases. Fusion status - PAX3: 
PAX3-FOXO1-positive; PAX7: PAX7-FOXO1-positive; n. a.: not applicable. 
Case 
Age at 
diagnosis 
(month) 
Sex Histology 
Fusion 
status 
Primary site 
Clinical 
stage 
(IRS) 
ARMS1 108 F alveolar PAX3 trunk III 
ARMS2 82 F alveolar PAX3 extremity III 
ARMS3 59 M alveolar negative trunk II 
ARMS4 5 F alveolar PAX7 uterus-vagina  III 
ARMS7 131 M alveolar PAX3 extremity IV 
ARMS36 7 F alveolar PAX3 trunk III 
ARMS37 90 F alveolar PAX3 uterus-vagina II 
ERMS1 63 M embryonal n. a. retroperitoneum III 
ERMS2 122 M embryonal n. a. bladder-prostate III 
ERMS3 61 M embryonal n. a. bladder-prostate III 
ERMS4 45 M embryonal n. a. trunk III 
ERMS12 18 M embryonal n. a. bladder-prostate III 
ERMS21 3 M embryonal n. a. retroperitoneum III 
ERMS23 37 F embryonal n. a. uterus-vagina II 
 
 
Cell lines and cultures 
Human alveolar (RH4 and RH30) and embryonal (RD and TE671) cell lines were 
maintained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM-HG) 
supplemented with 10% foetal bovine serum (FBS), 1% v/v L-glutamine, 100 μg/ml 
streptomycin and 100 U/ml penicillin, and grown at 37°C in a humidified atmosphere of 
5% CO2. To minimize the risk of working with misidentified and/or contaminated cell 
lines, we later stocked the cells used in this report at very low passages and used at <20 
subcultures. DNA profiling using the GenePrint 10 System (Promega Corporation, 
Madison, WI) was carried out to authenticate cell cultures, comparing the DNA profile of 
our cell cultures with those found in GenBank. Human foetal myoblast (HFM) cells were 
maintained in DMEM-HG supplemented with 20% FBS, 1% v/v L-glutamine, 100 μg/ml 
streptomycin and 100 U/ml penicillin, and grown at 37°C in a humidified atmosphere of 
5% CO2. 
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Transient transfection and RNA interference 
RD and TE671 cells were seeded at 2×105 cells/well in 12-well plates. Just a few hours 
before transfection, the DMEM-HG was removed, and after PBS (Calcium and 
Magnesium-Free Phosphate-Buffered Saline) wash, antibiotic free DMEM-HG medium 
was replaced.  Small interfering RNA (siRNA) against human DNMT3A (si-DNMT3A, 
sc-37757 by Santa Cruz Biotechnology, Dallas, TX), DNMT3B (si-DNMT3B, sc-37759 
by Santa Cruz Biotechnology) or siRNA negative control (si-NC, sc-37007 by Santa Cruz 
Biotechnology) were combined with RNAiMAX (Invitrogen) and used at 60 nM final 
concentration; si-DNMT3B is a pool of 3 target specific 19-25 nt siRNAs designed to 
specifically knock-down DNMT3B gene and this product was previously validated in other 
publication (Galli et al., 2013; Gravina et al., 2011). miRNA mimics (miR-29a-3p, 
MC12499 or miR-29c-3p, MC10518, Dharmacon Research) or negative control (miR-Ctr, 
Dharmacon Research) were transfected using Lipofectamine 2000 reagent (Life 
Technologies) at 50 nM final concentration, following the manufacturer’s protocol. The 
day after transfection, DMEM-HG was replaced, and cells were incubated at 37°C in 5% 
CO2 for different times. Cells were collected for cell cycle analysis, Q-PCR, western blot, 
immunofluorescence, migration, etc. at different times after transfection.  
 
 
Radiation exposure 
RD cells transfected with DNMT3A, DNMT3B or NC siRNAs were cultured for 48 h 
before radiation exposure. Radiation was delivered at room temperature using an x-6 MV 
photon linear accelerator. The total single dose of 4 Gy was delivered with a dose rate of 2 
Gy/min using a source-to-surface distance of 100 cm. Doses of 200 kV X-rays (Yxlon 
Y.TU 320; Yxlon, Copenhagen, Denmark) filtered with 0.5 mm Cu. The absorbed dose 
was measured using a Duplex dosimeter (PTW, Freiburg, Germany). The dose-rate was 
approximately 1.3 Gy/min and applied doses ranged from 0 to 600 cGy. At 72h post 
transfection and 24 h after radiation exposure, cells were collected for cell proliferation 
assay, colony formation assay, cell cycle analysis and western blot experiments. 
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RNA isolation 
Total RNA was extracted from samples and cell lines. Tumour tissues and NSM were 
disrupted and homogenised using TissueLyser II (QIAGEN) through the beating and 
grinding effect of beads on the sample material in an appropriate volume of TRIzol 
(Invitrogen, Carlsbad, CA). For RNA isolation from cell lines, 1 ml of TRIzol was added 
directly on the cell pellet.  From this point the protocol was the same for both tumour 
samples and cell lines. Briefly, the samples were incubated 5 minutes (min) at room 
temperature (RT) to allow the complete dissociation of nucleoprotein complexes. After 
adding of chloroform, samples were vortexed, incubated for 2-3 min at RT and 
centrifugated at 14000 rpm (rotation per minute) for 15 min at +4°C. The upper aqueous 
phase was recovered, and RNA was collected by alcohol precipitation using isopropanol. 
After incubation of 10 min at RT the samples were centrifugated at 14000 rpm for 10 min 
at +4°C. The supernatant was removed, and the pellet was washed twice in 75% ice-cold 
ethanol, then, after a further centrifugation step the ethanol was removed, and the nucleic 
acid pellet was allowed to dry before being resuspended in adequate volume of RNAse free 
water. RNA purity, integrity and quantity were checked using NanoDrop 2000 (Thermo 
Scientific, Waltham, MA).  
 
 
Reverse Transcription and Quantitative real time PCR (Q-PCR) 
Total RNA (2 μg) was subjected to reverse transcription with High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems, Foster City, CA). Master mix 2x was 
prepared as reported in Table 6A and then dispensed into the tubes containing RNA. 
Tubes were added on the 2720 Thermal Cycler (Applied Biosystem) machine and the 
program reported in Table 6B has run. 
Quantitative Real Time PCR (Q-PCR) for human DNMT1 (Hs00154749_m1), DNMT3A 
(Hs01027166_m1), DNMT3B (Hs00171876_m1) and MyHC (Hs00428600_ m1) mRNAs 
was performed using specific TaqMan RealTime Gene Expression Assays (Applied 
Biosystems) (Table 7A and 7B). 
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Table 6A                                                              Table 6B 
 
 
Table 7A                                                                        Table 7B 
 
 
Q-PCRs for human MYOD and Myogenin transcripts was carried out with the SensiFAST 
SYBR Hi-ROX Kit (Bioline, London, UK) (Table 8A and 8B). All Q-PCR assays were 
performed on a StepOne Real Time System (Applied Biosystems) machine. Samples were 
normalized according to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA 
levels. 
  
Table 8A                                                                    Table 8B 
 
 
Reverse transcription for human miR-133a (000458), miR206 (000510), miR-29a-3p, miR-
29c-3p was carried out with TaqMan MicroRNA Assay kit (Applied Biosystems) using 20 
ng of total RNA sample and the specific stem-loop primer as reported in the following 
tables (Table 9A, 9B, 9C and 9D): 
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Table 9A                                                          Table 9B 
 
 
Table 9C                                                                       Table 9D 
 
 
Data were normalized to U6 small nuclear RNA (RNU6, 001093) levels. The amount of 
each mRNA/miRNA was calculated by the comparative Ct method and expressed as fold 
change using the StepOne v2.3 software (Applied Biosystems). Each sample was run in 
triplicate in at least three independent experiments, unless specified differently in the 
figures. 
 
 
Cell proliferation assays 
Direct counting of RH4, RH30, RD and TE671 living cells was performed with trypan blue 
exclusion dye (Sigma-Aldrich, Saint Louis, MO) using the Countess II Automated Cell 
Counter (Thermo Fisher) at 72 h after si-DNMT3A, si-DNMT3B or si-NC transfection and 
after radiation exposure of RD cells or at 72 h post miRNA mimic transfection. 
Experiments were repeated at least three times, unless specified differently in the figures. 
Cell viability of the siRNA-transfected cells was determined by using MTT [3-(4,5-
dimethylthiazol2-yl)-2,5-diphenyltetrazolium] assay. RD cells (104) were plated onto 96-
well plates in sextuplicates and, after 24 h, transfected with synthetic DNMT3B siRNA; 
mocked control cells (transfected with si-NC) and blank cell-free wells were also included. 
35 
 
At designated times after transfection (0-24-48-72 h), 10 μl of MTT (5 mg/ ml, Sigma-
Aldrich) were added to each well and plates were incubated at 37°C for 3 h. Media were 
removed and 100 μl of DMSO was added into each well to dissolve the dark blue formazan 
crystals. Absorbance was read at wavelength of 550 nm, with reference at 630 nm, using a 
microtitre plate reader (SelectScience, Corston, UK). The percentage cellular viability was 
calculated with the appropriate controls taken into account. The results were plotted as 
means ± SD of two separate experiments having six determinations per assay for each 
experimental condition. 
 
 
Morphological assessment of siRNA-transfected cells 
An Axio Vert.A1 microscope (Carl Zeiss Microscopy, Thornwood, NY), furnished with an 
AxioCam MRc5 camera (Carl Zeiss Microscopy) was used to observe the morphological 
changes of the cells transfected with si-DNMT3A, si-DNMT3B or si-NC siRNAs. Cells 
were photographed at 72 and 144 h post-transfection using a 20x magnification. Images 
were analysed by using the ImageJ software (NIH ImageJ 1.47). 
 
 
Cell cycle analysis 
In order to study cell cycle distribution, RH4, RH30, RD and TE671 cells, transfected with 
DNMT3A, DNMT3B or NC siRNAs for 48 h, RD cells, transfected with miR-29a-3p, 
miR-29c-3p or miR-Ctr for 48 h, and RD cells 24 h after radiation exposure, were 
trypsinised, centrifugated at 1500 rpm for 5 min at + 4 °C and washed twice in ice-cold 
PBS. Cells were counted and at least 106 cells were fixed in 70% ice-cold ethanol 
overnight at +4°C. The day after, cells pellets were washed twice in ice-cold PBS, treated 
with RNase A (50 μg/ml) for 30 min at 37°C and then stained with propidium iodide (10 
μg/ml) solution. DNA content was measured by BD FACSCalibur Flow Cytometer (BD 
Biosciences, San Jose, CA). Data were analysed using ModFit 3.1 software (BD 
Biosciences). Experiments were carried out three times, unless specified differently in the 
figures. 
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Apoptosis analysis 
Apoptosis was analysed by flow cytometry using PE Annexin V Apoptosis Detection Kit I 
(BD Biosciences). Briefly, floating and attached RD cells transfected with DNMT3B or 
NC siRNAs were collected at 72 h after transfection, washed twice in ice-cold PBS and 
resuspended in fresh 1x Annexin V Binding Buffer at a concentration of 106 cells/ml. 
Approximately 2x105 cells were stained with Annexin V and 7-Amino-Actinomycin (7-
AAD) for 15 min at RT in the dark according to the manufacturer’s instructions. Annexin 
V and 7-AAD fluorescence intensities of control or treated samples were analysed using a 
BD FACSCalibur (BD Biosciences). Data were collected and analysed using Cell Quest 
Pro software (BD Biosciences). Experiments were performed three times. 
 
 
Trans-well migration assay  
For cell migration assay, BD FalconTM Cell Culture Inserts with 8 μm pore polycarbonate 
filters were placed into a 24-well culture plate. Briefly, serum-free cell suspension, 
containing 105 si-DNMT3B, si-NC, miR-29a-3p, miR-29c-3p or miR-Ctr RD cells, was 
added to the upper compartment of the chamber at 48 h post-transfection. The lower 
compartment contained DMEM-HG with 10% FBS, used as chemoattractant. After 
incubation at 37°C for additional 24 h, the inserts were washed twice in PBS and migrated 
cells at the base of the inserts were fixed in 100% methanol for 20 min at -20°C. After two 
washing in PBS, cells were stained with 0.1% crystal violet dye in 25% methanol for 5 min 
at RT. Non-migrating cells on the upper surface of the membrane were removed with 
cotton swabs and then the inserts were washed in water and allowed to dry. Cells were 
photographed under a light microscope at 10x. The area occupied by migrated cells in si-
DNMT3B and si-NC samples was measured by using the ImageJ software 
(http://imagej.nih.gov/ij/). Experiments were carried out three times, unless specified 
differently in the figures. 
 
 
Colony formation assay 
For anchorage-dependent colony formation assays, RD cells after DNMT3A, DNMT3B or 
NC-siRNA transfection, irradiated or not with 4 Gy and miR-29a-3p, miR-29c-3p or miR-
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Ctr RD cells were plated in 6-well plates at 4×103 cells/well and cultured for 11 days. 
Colonies were washed twice in PBS and fixed in 100% methanol for 20 min at -20°C. 
After two washing in PBS, cells were stained with 0.1% crystal violet dye in 25% 
methanol for 10 min at RT. Colonies were washed in water, allowed to dry and finally 
photographed. To quantify colonies, crystal violet was solubilized in 30% acetic acid in 
water for 15 min at RT and absorbance was measured using the Biochrom Libra S22 
UV/VIS spectrophotometer (Biochrom, Berlin, DE) at wavelength of 595 nm; 30% acetic 
acid in water was used as the blank. Assays were carried out three times, unless specified 
differently in the figures. 
 
 
U0126 treatment  
RD and TE671 cells were seeded at 4x105 cells/well in 6-well plates. After 24 h, the 
MEK/ERK inhibitor U0126 (Santa Cruz Biotechnology) was added to a final concentration 
of 10 μM. Following different times of treatment, cells were collected for western blot and 
Q-PCR experiments. Mocked control cells were treated with DMSO.  
 
 
Protein extracts and western blot analysis 
RH4, RH30, RD and TE671 cells, transfected with siRNAs/miRNA mimics, treated with 
U0126 or after radiation exposure, were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 
50 mM tris-HCl pH 8, 0.5% deoxycholic acid, 0.1% SDS, 1 mM PMSF, 1 μg/ml leupeptin, 
1 μg/ml aprotinin, 1x protease inhibitor, 1 mM Na3VO4 and 50 mM NaF) for 20 min on ice. 
Samples were centrifugated at 14000 rpm for 10 min at +4°C, and the supernatant, 
containing total protein, was recovered. Protein extracts were quantified using the Biorad 
Protein Assay Kit (Biorad, Berkeley, CA) by measuring the absorbance of samples and 
BSA (bovine serum albumin) standard curve at wavelength of 595 nm. Total protein 
extracts (30 μg) were separated on 6-15 % sodium dodecyl sulfate (SDS) polyacrylamide 
gel (100 V for about 2 h) and transferred (250 mA for about 1 h 30 min) onto 
polyvinylidene fluoride (PVDF) membranes (EMD Millipore Corporation, Billerica, MA). 
Filters were stained in Ponceau S solution (Sigma-Aldrich), washed in 1x PBS with 0.1% 
Tween (PBS-T) and then blocked in 5 % not-fat milk or 3% BSA and incubated over-night 
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at +4 °C or 2 h at RT with the following primary antibodies: Bcl-xL, Cyclin B1, Cyclin E2, 
DNMT3B, E2F1, p21, p27, Caveolin 1, DNA-PKcs, ATM, and RAD51 by Santa Cruz 
Biotechnology; cleaved PARP, MYOD1, Myogenin and MyHC by EMD Millipore 
Corporation; DNMT1 and DNMT3A by GeneTex, Irvine, CA; Cyclin D1 by MBL 
International, Woburn, MA; phospho-pRB at Ser807/811 (p-RB), total RB, phospho-p38 at 
Thr180/Tyr182, total p38 and phospho-H2AX by Cell Signalling Technology, Danvers, 
MA. Filters were washed three times in PBS-T and were incubated with appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibodies (Santa Cruz Biotechnology) 
for 1 h at RT. After three washing in PBS-T protein signals were detected using 
WesternBright ECL kit (Advansta, Menlo Park, CA), according to the manufacturer’s 
instructions, and visualized by ChemiDoc XRS+ (Bio-Rad). Tubulin (Sigma-Aldrich) was 
used as a normalization control for equal loading. Densitometry was performed to quantify 
changes in protein expression using the Image Lab 5.1 software (Bio-Rad). Briefly, signal 
intensity for each band was calculated by the local subtraction method. DNMT3B protein 
levels in si-DNMT3B samples were then normalized and reported as relative expression 
with respect to si-NC cells. All experiments were carried out at least three times, unless 
specified differently in the figures. 
 
 
Immunofluorescence 
RD and TE671 cells transfected with DNMT3B or NC siRNAs were cultured for 48 h 
before plating 105 cells per well in 24-well plates with 2% gelatine-coated glasses. After 
one additional day, cells were washed twice in PBS and fixed in 4% paraformaldehyde 
(PFA) in PBS for 30 min at RT, followed by treatment with 0.1 M glycine in PBS for 20 
min at RT and with 0.1 % Triton X-100 in PBS for additional 5 min at RT to allow 
permeabilization. Cells were incubated for 1 h at RT with the following primary antibodies: 
Cyclin B1, DNMT3B, E2F1 and p21 (Santa Cruz Biotechnology); MYOD1 and MyHC 
(EMD Millipore Corporation); Cyclin D1 (MBL International); p-RB (Cell Signalling 
Technology). After washing in PBS, cells were incubated with appropriate Texas Red-
coniugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA,) for 30 min 
at RT in the dark. Nuclei were counter-stained with 1 μg/ml 4', 6-diamido-2phenylindole 
dihydrochloride (DAPI, Sigma-Aldrich). Labelled cover-slips mounted in Moviol were 
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acquired with Zeiss ApoTome and Axiovision software (Carl Zeiss) using a 40x 
magnification. Experiments were replicated twice. 
 
 
Statistical analysis  
Data were expressed as mean ± standard deviation (SD) of each condition. Statistical 
significance between groups was assessed by Student’s t-test and probability (p) values of 
less than 0.05 were accepted as significant. 
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RESULTS 
 
 
Expression of DNMT1, DNMT3A and DNMT3B in RMS tumours and 
cell lines 
To explore the association between DNA methylation and RMS, transcript levels of 
DNMT1, DNMT3A and DNMT3B genes were assessed in 14 RMS primary tumours, 7 
ARMSs and 7 ERMSs, by using Real Time PCR. DNMTs levels were significantly up-
regulated in all tumour samples in comparison to NSM, used as normal tissue, with an 
average increase of 30.5±9.0, in accordance with previously published data (Chen et al., 
1999), 22.0±3.3 and 81.2±9.4, respectively (Figure 12 and 13). Therefore, we focused on 
DNMT3B enzyme, whose over-expression was also confirmed in ARMS (RH4 and RH30) 
and ERMS (RD and TE671) cell lines both at mRNA and protein levels (Figure 14A and 
14B). 
 
 
Figure 12: DNMT1 and DNMT3A expression in RMS tumours. Q-PCR analysis of DNMT1 
and DNMT3A mRNA levels in 7 ARMSs and 7 ERMSs, expressed as fold increase over NSM, 
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arbitrarily set at 1. Transcript levels were normalized to GAPDH mRNA and error bars represent 
standard deviation (SD) of two independent Q-PCR reactions, each performed in triplicate. 
 
 
Figure 13: DNMT3B expression in RMS tumours. Q-PCR analysis of DNMT3B mRNA levels 
in 7 ARMSs and 7 ERMSs, expressed as fold increase over NSM, arbitrarily set at 1. Transcript 
levels were normalized to GAPDH mRNA and error bars represent standard deviation (SD) of two 
independent Q-PCR reactions, each performed in triplicate. 
 
 
Figure 14: DNMT3B expression in RMS cell lines. A) Q-PCR of DNMT3B mRNA levels in 
ARMS (RH4 and RH30) and ERMS (RD and TE671) cell lines, expressed as fold increase over 
NSM, arbitrarily set at 1. GAPDH was used as endogenous control. Bars represent mean values of 
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three independent experiments, each performed in triplicate. HFM, human foetal myoblats. B) 
Western blot showing the expression of DNMT3B protein in RH4, RH30, RD and TE671 cell lines. 
Tubulin was used as loading control. Representative of three different experiments. 
 
 
siRNA transfection down-regulates DNMT3B expression and inhibits 
RMS cell proliferation 
To evaluate the effect of DNMT3B enzyme on the phenotype of RMS cells, we used a 
specific small interfering RNA (siRNA) against DNMT3B mRNA in RD cell line, an in 
vitro model of ERMS. siRNA transfections were performed in RD cells cultured in growth 
medium, i.e. supplemented with 10% serum. DNMT3B knock-down efficiency was 
assessed by using Q-PCR and western blot analysis at 72 h after transfection. A significant 
reduction of DNMT3B at both mRNA (0.5-fold) and protein (0.5- fold) levels (Figure 15A 
and 15B) was observed in si-DNMT3B cells compared to those transfected with the 
negative control siRNA (si-NC). DNMT1 and DNMT3A expression was not significantly 
perturbed by transient si-DNMT3B transfection, this assessing a specific silencing (Figure 
15A and 15B). Immnunoflurescence experiments showed a strong nuclear distribution of 
DNMT3B protein in mocked control RD cells, whit a remarkable decline in its expression 
upon si-DNMT3B transfection (Figure 15C). At 72 h after transfection, direct counting for 
living cells using trypan blue dye exclusion test confirmed that DNMT3B depletion 
drastically inhibited the proliferation potential of RD cells compared to si-NC cells (Figure 
16A). Similar results were obtained by MTT assay, which showed a significant decrease of 
cellular viability/proliferation rate in si-DNMT3B compared to si-NC transfected cultures, 
with a peak of about 50% at 72 h post transfection (Figure 16B). DNMT3B siRNA 
transfection carried out in a second ERMS cell line (TE671) gave overlapping results, 
showing a marked reduction in DNMT3B protein levels and a down-regulation of the 
enzyme in the nuclear compartment (Figure 17A and 17B). DNMT3B knocked-down 
TE671 cells also exhibited a minor cell growth rate (Figure 17C). 
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Figure 15: DNMT3B knock-down by RNA interfering in RD cells. A) DNMT transcript levels 
measured by Q-PCR at 72 h in RD cells after transfection with si-DNMT3B in comparison to 
samples transfected with si-NC, arbitrarily set at 1. GAPDH was used as a control. Shown are the 
means of four independent experiments. Error bars represent SD of the means. Asterisks represent 
the statistical significance (***, p<0.001; ns, not significant). B) Western blots showing the 
expression of DNMT3B protein at 72 h after si-DNMT3B transfection compared to si-NC cells. 
Tubulin was used as loading control. DNMT1 and DNMT3A protein levels were not perturbed by 
si-DNMT3B delivery. Representative of three independent experiments. C) Representative 
immunofluorescence showing the down-regulation of DNMT3B protein levels in nuclear 
compartment at 72 h after si-DNMT3B transfection. High levels of DNMT3B were evident in the 
nuclei of si-NC cells. 
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Figure 16: Depletion of DNMT3B inhibits RD cell proliferation. A) Viability of RD cells 72 h 
post-transfection with DNMT3B siRNA calculated with respect to control si-NC cells, assessed by 
trypan blue exclusion staining. Results represent the mean value of four independent experiments ± 
SD. Statistical significance: **, p<0.01. B) MTT assay performed to assess relative RD cell 
numbers at different point after si-DNMT3B or si-NC transfection (0-24-48-72 h). Each point is the 
mean of three replicate wells ± SD and is representative of three independent experiments.  
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Figure 17: RNA interfering-mediated DNMT3B knock-down affects TE671 cell viability. A) 
Western blot showing the expression of DNMT3B protein in TE671 cells at 72 h after si-DNMT3B 
transfection compared to si-NC sample. Tubulin was used as loading control. B) Representative 
immunofluorescence showing the down-regulation of DNMT3B protein levels in nuclear 
compartment at 72 h after si-DNMT3B transfection. High levels of DNMT3B were evident in the 
nuclei of si-NC cells. C) Viability of TE671 cells 72 h post-transfection with DNMT3B siRNA 
calculated with respect to control si-NC cells, assessed by trypan blue exclusion staining. Results 
represent the mean value of four independent experiments ± SD. Statistical significance: **, p<0.01. 
 
 
Decreased DNMT3B expression induces G1 cell cycle arrest  
To further determine whether the reduced RD cell growth was due to alterations in cell 
cycle progression, flow cytometry analysis was performed. Based on propidium iodide 
staining of cellular DNA content, DNMT3B down-regulation resulted in a significant 
increase of cell percentage in G1 phase (p<0.005) with a concomitant decrease of cell 
percentage in S and G2 phases (G1: 78.0±2.8%, S: 15.1±2.5%, G2: 6.9±0.27%), whilst si-
NC transfected cells rapidly divided and progressed through the cell cycle at high rates (G1: 
43.5±0.7%, S: 44.9±2.0%, G2: 11.6±1.3%) (Figure 18). 
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Figure 18: Cell cycle distribution. Flow cytometry data showing percentages of cells in G1, S and 
G2 phases in si-DNMT3B and si-NC RD cells at 48 h after transfection. Data are average values of 
three independent experiments. 
 
Consistent with G1 arrest, the expression of different cell cycle regulators was modulated 
with a marked decrease of Cyclin B1, Cyclin D1 and Cyclin E2 expression (Figure 19A) 
and a simultaneous up-regulation of p21 and p27 levels in DNMT3B depleted cells 
(Figure 19A). Moreover, DNMT3B knock-down also efficiently abolished the 
phosphorylation status of retinoblastoma (RB) tumour suppressor (p-RB) and induced a 
parallel slight reduction in E2F1 levels (0.2-fold), this confirming the cell cycle block at 
G1 phase (Figure 19A). In accordance with western blotting expression results, 
immunofluorescence experiments also showed that si-DNMT3B transfection caused a 
strong reduction of Cyclin D1 nuclear staining with a dramatic up-regulation and 
relocalization of p21 in the nuclear compartment (Figure 19B). Consistent with the RB 
activity in its underphosphorylated state, nuclear shuttling of the E2F1 transcriptional 
factor was not evident in si-DNMT3B cells compared to si-NC samples (Figure 19B). 
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Figure 19: DNMT3B knock-down alters the expression of specific cell cycle regulators in RD 
cells. A) Western blot analyses of a panel of cell cycle regulatory proteins in RD cells at 72 h after 
si-NC or si-DNMT3B transfection. Tubulin expression was used as the internal control. 
Representative blots of three independent experiments. B) Immunofluorescence experiments 
showing the expression and localization of Cyclin B1, Cyclin D1, p21, p-RB and E2F1 proteins in 
RD cells at 72 h after DNMT3B or NC siRNA transfection. DAPI was used for nuclear staining. 
Images captured under ApoTome microscope at 40x magnification. 
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DNMT3B involvement in apoptosis and migration of RMS cells 
To evaluate whether the reduced number of cells was due, not only to cell cycle arrest, but 
also to apoptosis, flow cytometry experiments were performed. FACS analysis showed that 
programmed cell death was not affected by DNMT3B knock-down since no significant 
changes in early or late apoptosis rates were observed in si-DNMT3B compared to si-NC 
transfected cells (Figure 20A). Furthermore, the expression levels of some specific 
apoptosis markers, such as cleaved PARP and Bcl-xL, resulted similar in DNMT3B-
depleted cells and in negative control samples (Figure 20B). 
 
 
Figure 20: Decreased DNMT3B does not affect apoptosis. A) Histogram showing the rate of 
apoptosis in RD si-NC (2.23%) and si-DNMT3B (4.3%) cells at 72 h after transfection. Cells were 
stained with Annexin V and 7-AAD followed by FACS analysis. B) Western blots showing the 
expression of PARP and Bcl-xL proteins in si-DNMT3B and si-NC RD cells. Tubulin was used as 
loading control. 
 
DNMT3B silencing significantly impaired the ability of RD cells to migrate through the 
non-matrigel-coated membranes towards serum-containing medium with respect to si-NC 
controls (0.5-fold) (Figure 21A). Furthermore, when allowed to grow at low density, si-
DNMT3B cells showed a lower ability to form colonies in anchorage-dependent 
experiments compared to control cells, with a 0.6-fold of crystal violet absorbance (Figure 
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21B). Taken together, these results indicated that the in vitro under-expression of 
DNMT3B is able to inhibit RMS progression by reducing cell proliferation and migration. 
 
 
Figure 21: DNMT3B reduction correlates with altered migration and clonogenic ability of RD 
cells. A) Representative images of migrated cells using the transwell migration assay 
(magnification of 10x). Data in the histograms are expressed as the means ± SD from three separate 
experiments, each performed in triplicate (**, p<0.01). B) Colony forming efficiency was 
calculated by crystal violet absorbance from three independent experiments, each performed in 
triplicate (*, p<0.05). 
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DNMT3B knock-down promotes myogenic differentiation in RMS cells 
DNMT3B silenced RD cells exhibited a substantial change in their morphology with more 
elongated cellular bodies already after 72 h post-siRNA transfection and with an increased 
number of multinucleated myotube-like structures at 144 h after transfection (Figure 22A), 
whilst si-NC showed the typical round proliferative shape (Figure 22A). The expression of 
specific muscle skeletal markers was thus evaluated. A sustained increase of MYOD1, 
Myogenin and MyHC at mRNA and protein levels was observed in both Q-PCR and 
immunoblotting assays, performed 72 h after DNMT3B silencing respect to si-NC 
transfection (Figure 22B and 22C). In immunofluorescence experiments, MYOD1 factor 
exhibited a more evident granular staining in nuclear envelope in si-DNMT3B transfected 
RD cells in comparison to si-NC samples (Figure 22D); furthermore, elongated myotube-
like si-DNMT3B cells displayed a strong fluorescence of MyHC, a marker of committed 
muscle cells (Figure 22D), indicating that the proper myogenic differentiation was 
triggered by the reduction of the DNMT3B levels. Notably, the phenotypic effect of 
DNMT3B knock-down in RD cells was also observed at 144 h post-transfection, with even 
lower levels of DNMT3B itself and higher levels of MyHC protein (Figure 22E), 
confirming that the commitment to terminal myogenic differentiation was preserved. 
Finally, we investigated whether DNMT3B was also involved in the regulation of specific 
miRNA levels. Indeed, we demonstrated that DNMT3B depletion was able to significantly 
up-regulate the expression of miR-133a and miR-206, two well-established myomiRs 
essential in promoting muscle cell differentiation (Figure 22F). DNMT3B knocked-down 
TE671 cells also exhibited a more elongated morphology than mocked control cells at both 
72 and 144 h post-transfection (Figure 23A), and showed up-regulation of myogenic 
differentiation markers MYOD1, Myogenin and MyHC at 72 h post-siRNA injection 
(Figure 23B). Moreover, immunofluorescence experiments confirmed that DNMT3B 
silencing caused over-expression and nuclear staining of MYOD1 and a stronger signal 
intensity of MyHC in si-DNMT3B cells than in control cells (Figure 23C). 
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Figure 22: DNMT3B silencing by RNA-interference triggers myogenic differentiation in RD 
cells. A) Cellular morphology of si-NC and si-DNMT3B RD cells was analysed under light 
microscope at 20x magnification at 72 and 144 h after siRNA transfection. In si-DNMT3B cultures, 
more elongated cellular bodies were evident, many of which formed multinucleated myotube-like 
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structures. B) Expression of myogenic genes, MYOD1, Myogenin and MyHC, by Q-PCR assays in 
RD cells transfected with DNMT3B or NC siRNAs for 72 h. Expression of each mRNA was 
normalized to GADPH levels and plotted as fold change relative to si-NC samples. Histograms are 
means ± SD. Asterisks represent the statistical significance (**, p<0.01; ***, p<0.001). C) Western 
blots showing the expression of MYOD1, Myogenin and MyHC proteins in si-DNMT3B and si-
NC RD cells at 72 h post-transfection. Tubulin was used as loading control. Representative of three 
different experiments. D) Immunofluorescence experiments showing the expression and 
localization of MYOD1 and MyHC at 72 h after DNMT3B or NC siRNA transfection. DAPI was 
used for nuclear staining. Images captured under ApoTome microscope at 40x magnification. E) 
Western blots showing the expression of DNMT3B and MyHC proteins in si-DNMT3B and si-NC 
RD cells at 144 h post-transfection. Tubulin was used as loading control. F) Expression of 
myogenic miRNAs, miR-133a and miR-206, by Q-PCR experiments in RD cells transfected with 
DNMT3B or NC siRNAs for 72 h. Expression of each miRNA was normalized to U6 levels and 
plotted as fold change relative to si-NC samples. Histograms are means ± SD. Asterisks represent 
the statistical significance (**, p<0.01; ***, p<0.001). 
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Figure 23: DNMT3B knock-down induces terminal myogenic differentiation in TE671 cells. 
A) Cellular morphology of si-NC and siDNMT3B TE671 cells was analysed under light 
microscope at 20x magnification at 72 and 144 h after siRNA transfection. In si-DNMT3B cultures, 
more elongated cellular bodies were evident, many of which formed multinucleated myotube-like 
structures. B) Western blots showing the expression of MYOD1, Myogenin and MyHC proteins in 
si-DNMT3B and si-NC TE671 cells at 72 h post-transfection. Tubulin was used as loading control. 
Representative of three different experiments. C) Immunofluorescence experiments showing the 
expression and localization of MYOD1 and MyHC at 72 h after DNMT3B or NC siRNA 
transfection. DAPI was used for nuclear staining. Images captured under ApoTome microscope at 
40x magnification. 
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MEK/ERK inhibitor U0126 down-regulates DNMT3B protein expression 
Since the MEK/ERK cascade is aberrantly activated in RMS and its inhibition has been 
shown to affect tumour growth and to rescue skeletal muscle differentiation in ERMS cells 
(Marampon et al., 2006), as occurred in si-DNMT3B transfected cells, we studied if 
DNMT3B expression could be linked to the MEK/ERK signalling pathway. RD cells 
treated with the MEK/ERK inhibitor U0126 (10 μM) for 96 h were able to fully 
differentiate, as assessed by the up-regulation of MYOD1, Myogenin, MyHC, miR-133a 
and miR-206 levels, but also showed a decreased expression of DNMT3B protein (Figure 
24A and 24B). Interestingly, a drastic reduction of DNMT3B enzyme was observed at 
early points of U0126 treatment (12-24 h) in RD cells, subsequently to the down-regulation 
of ERK phosphorylation status, evident at 6 h post-exposure (Figure 24C). TE671 cells 
treated with U0126 showed matched results (Figure 24C).  
Considering the evidence that U0126 treatment is able to activate p38 kinase for promoting 
myosin expression in RMS cells (Marampon et al., 2006; Mauro et al., 2002), p38 
phosphorylated levels were analysed in DNMT3B depleted cells. A long-lasting increase 
of p38 phosphorylation (p-p38) was observed in si-DNMT3B transfected cells in 
comparison to si-NC samples both at 72 and 144 h in RD and TE671 cell lines (Figure 25). 
Altogether, these data indicate that DNMT3B is a down-stream component of the 
MEK/ERK signalling pathway and that abrogation of this enzyme is an essential step in the 
U0126-mediated capacity of ERMS cells to rescue myogenic differentiation program. 
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Figure 24: Inhibition of MEK/ERK pathway by U0126 down-regulates DNMT3B. A) Western 
blots showing the down-regulation of DNMT3B and the up-regulation of MYOD1, Myogenin and 
MyHC in RD cells treated with U0126 for 96 h. Mocked control cells were treated with DMSO. 
Tubulin was used as loading control. Representative of three different assays. B) Expression of 
myogenic miRNAs, miR-133a and miR-206, by Q-PCR experiments in RD cells treated with 
DMSO or U0126 for 96 h. Expression of each miRNA was normalized to U6 levels and plotted as 
fold change relative to control samples. Histograms are means ± SD. Asterisks represent the 
statistical significance (*, p<0.05; **, p<0.01). C) Time-course experiments showing the early 
decreased phosphorylation status of ERK and the down-stream reduced expression of DNMT3B 
protein in RD and TE671 cells upon U0126 treatment for 0-6-12-24-48-96 h. Tubulin was used as 
loading control. Representative of two different assays. 
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Figure 25: DNMT3B knock-down activates p38 kinase in ERMS cells. Western blots showing 
phosphorylated and total p38 levels in si-DNMT3B and si-NC RD and TE671 RMS cells at 72 and 
144 h post-transfection. Tubulin was used as loading control. Representative of two different 
assays. 
 
 
Down-regulation of miR-29a/c contributes to altered expression of 
DNMT3B in RMS cells 
Since the importance of microRNAs in physiological processes and tumorigenesis and the 
implication of miR-29 family in skeletal muscle differentiation (Wang et al., 2008a), we 
analysed if DNMT3B expression could be linked to these miRNAs. Based on deep-
sequencing of miRNA profile in RMS biopsies, previously carried out in our laboratory 
(Megiorni et al., 2014), we focused on miR-29a-3p and miR-29c-3p expression levels. The 
down-regulation of both miRNAs was confirmed in 14 RMS tumour tissues, 7 ARMSs and 
7 ERMSs, by Q-PCR experiments. In agreement with deep-sequencing findings, a strong 
down-regulation of both miR-29a-3p and miR-29c-3p was observed in all tumour samples 
in comparison to NSM (Figure 26), with an average decrease of 0.1±0.19 and 0.02±0.04, 
respectively. To predict whether DNMT3B was a target of miR-29a-3p and miR-29c-3p, 
TargetScan Human (Release 7.1) and DIANA-microT algorithms were interrogated, 
showing a perfect complementary between DNMT3B mRNA and the seed-sequence of 
both miR-29a-3p and miR-29c-3p (Figure 27).  
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Figure 26: miR-29 expression in RMS tumours. Q-PCR showing the expression levels of miR-
29a-3p and miR-29c-3p in 7 ARMSs and 7 ERMSs, expressed as fold increase over NSM, 
arbitrarily set at 1. Transcript levels were normalized to U6 small nuclear RNA levels and error 
bars represent SD of two independent Q-PCR reactions, each performed in triplicate. 
 
 
Figure 27: Seed sequence of miR-29a-3p and miR-29c-3p on DNMT3B transcript. Sequence 
alignment of miR-29a-3p and miR-29c-3p seed sequences at miRNA 5’-end (bottom) and 
DNMT3B 3’-UTR binding sites (top). Data from TargetScanHuman 7.1 interrogation. 
 
To validate the in silico analysis, transient transfections, in RD cells, were carried out. A 
miRNA duplex from C. elegans was used as a negative miRNA-Control (miR-Ctr). By 
using stem-loop real-time PCR, specific expression increase of miR-29a-3p (226-fold) and 
miR-29c-3p (115-fold) after transfection with the respective mimic was demonstrated 
(Figure 28A). A significant down-regulation of the endogenous DNMT3B at both mRNA 
and protein levels was observed in miR-29a-3p/miR-29c-3p RD cells at 72 h after 
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transfection compared to those transfected with miR-Ctr (Figure 28B and 28C), consistent 
with the conserved binding sites for these miRNAs in the 3’-untranslated region of the 
DNMT3B transcript, identified by computational tools for miRNA target prediction. 
In order to determine whether the restoration of normal miR-29a-3p and miR-29c-3p 
expression levels induced similar effects on RD cells, to those observed after si-DNMT3B 
transfection, a series of in vitro gain of function experiments were performed. Direct 
counting for living cells using trypan blue dye exclusion test showed a decrease of cell 
proliferation at 72 h after to transfection with both miRNA mimics (0.6-fold) (Figure 29A). 
Furthermore, the reduced RD cell growth was due to alterations in cell cycle progression, 
as shown from flow cytometry analysis. Propidium iodide staining highlighted an increase 
of cell percentage in G1 phase with a concomitant decrease of cell percentage in S and G2 
phases (Figure 29B) in both miR-29a-3p and miR-29c-3p cells in comparison to miR-Ctr 
cells, as well as observed in si-DNMT3B RD cells. 
Ectopic expression of miR-29a-3p and miR-29c-3p decreased the ability of RD cells to 
migrate through non-matrigel-coated membranes towards serum-containing medium when 
compared with a mimic negative control (Figure 30A). Finally, when allowed to grow at 
low density, miR-29a-3p and miR-29c-3p cells showed a lower ability to form colonies in 
anchorage-dependent experiments compared to control cells (Figure 30B). Altogether, 
these data suggest that miR-29a/c down-regulation observed in RMS contributes to 
abnormal expression of DNMT3B, thus promoting its oncogenic activity.  
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Figure 28: DNMT3B is a target of miR-29 in RMS cells. A) Relative expression of miR-29a-3p 
and miR-29c-3p measured by Q-PCR at 72 h in RD cells after transfection with the respective 
miRNA mimics in comparison to samples transfected with miR-Ctr, arbitrarily set at 1. U6 was 
used as a control. Error bars represent SD of the means of two independent experiments, each 
performed in triplicate, (***, p<0.001). B) Q-PCR showing the expression of DNMT3B mRNA, 
expressed as fold increase in respect to miR-Ctr cells, after miRNA mimics transfection.  Bars 
represent mean values of two independent experiments, each performed in triplicate. Statistical 
significance: ***, p<0.001; **, p<0.01.  C) western blot showing the down-regulation of DNMT3B 
protein levels in RD cells at 72 h after transfection with miR-29a-3p and miR-29c-3p in 
comparison to miR-Ctr. Tubulin was used as loading control. 
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Figure 29: miR-29a-3p and miR-29c-3p impair RMS cell growth. A) Viability of RD cells 72 h 
post-transfection with miR-29a-3p and miR-29c-3p in comparison to control miR-Ctr cells, as 
assessed by trypan blue exclusion staining. Results represent the mean value of two independent 
experiments ± SD. Statistical significance: **, p<0.01; *, p<0.05. B) Flow cytometry data showing 
percentages of cells in G1, S and G2 phases in miR-29a-3p and miR-29c-3p or miR-Ctr RD cells at 
48 h after transfection. Data are representative of two independent experiments. 
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Figure 30: miR-29a-3p and miR-29c-3p decrease migration and clonogenic abilitiy of RD cells. 
A) Representative images of migrated cells using the transwell migration assay from two separate 
experiments, each performed in triplicate (magnification of 10x). B) Representative images of 
clonogenic ability of miR-29a-3p and miR-29c-3p cells in anchorage-dependent experiments 
compared to negative control cells.  
 
 
Depletion of DNMT3B in alveolar RMS cell line does not have effects on 
proliferation and differentiation 
Based on the up-regulation of DNMT3B in alveolar RMS tumour sample and the 
expression at both mRNA and protein levels in ARMS cell line in comparison to NSM, 
showed previously by Q-PCR and western blot, different experiments were performed on 
RH4 and RH30 cells to evaluate the possible effects of DNMT3B silencing in alveolar 
subtype. Direct counting for living cells using trypan blue dye exclusion test carried out at 
72 h after transfection showed that DNMT3B knock-down did not affect the proliferation 
of RH4 and RH30 cells respect to si-NC cells (Figure 31).  
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Figure 31: DNMT3B knock-down by RNA interference does not affect cell viability of ARMS 
cells. A) Viability of RH4 and RH30 cells 72 h post-transfection with DNMT3B siRNA calculated 
with respect to control si-NC cells, assessed by trypan blue exclusion staining. Results represent the 
mean value of three independent experiments ± SD (ns, not significant). 
 
Furthermore, flow cytometry analysis performed on RH4 and RH30 transfected with si-
DNMT3B for 48 h did not highlight alterations in cell cycle progression in comparison to 
those transfected with si-NC (Figure 32). 
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Figure 32: Cell cycle distribution of RH4 and RH30 cells. Flow cytometry data showing 
percentages of cells in G1, S and G2 phases in si-DNMT3B and si-NC ARMS cells at 48 h after 
transfection. Data are average values of two independent experiments.  
 
Finally, unlike the RD cells, silencing of DNMT3B did not reactivate myogenic 
differentiation in RH4 and RH30 cells, as shown by the specific muscle markers protein 
levels analysed by western blot at 72 h post transfection (Figure 33). Indeed, the 
expression levels of MYOD1 and Myogenin did not increase in DNMT3B depleted ARMS 
cells respect to si-NC cells and the terminal differentiation marker, MyHC, was not 
detected (Figure 33). 
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Figure 33: DNMT3B silencing by RNA-interference does not induces myogenic 
differentiation in alveolar RMS cells.  Western blots showing the expression levels of MYOD1, 
Myogenin and MyHC in RH4 and RH30 cells transfected with si-DNMT3B or si-NC for 72 h. RD 
cells treated with U0126 ware used as positive control, whilst tubulin was used as loading control. 
Representative of two different assays. 
 
 
Loss of DNMT3A expression does not alter RMS cells phenotype 
Since the up-regulation of DNMT3A in all tumour samples showed by Q-PCR in 
comparison to NSM, we evaluated whether the knock-down of this de novo DNA 
methyltransferase had the same effects of DNMT3B knock-down on the phenotype of 
RMS cells. Using a specific siRNA against DNMT3A mRNA in RD cell line, at 72 h after 
transfection, direct counting for living cells using trypan blue dye exclusion test showed 
that DNMT3A depletion did not affect the proliferation of RD cells respect to si-NC cells 
(Figure 34A). In addition, unlike si-DNMT3B transfected RD cells, propidium iodide 
staining of cellular DNA content, showed the same cell percentage in G1 phase in si-
DNMT3A (62.49%) compared with si-NC (59.88%) transfected cells and a mild increase 
of cell number in G2 phase (si-NC, 5.4%, si-DNMT3A, 12.86%), with a concomitant 
slight decrease of cell percentage in S phase (si-NC, 34.72%, si-DNMT3A, 24.65%) 
(Figure 34B). The study of specific cell cycle markers, detected by western blot 
experiments, confirmed the flow cytometry analysis. As shown in Figure 34C, cyclin B 
protein level was increased in si-DNMT3A RD cells, whilst cyclin D1 was down-regulated 
in comparison to control cells.  
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Figure 34: DNMT3A knock-down does not affect cell viability in RD cells. A) Viability of RD 
cells 72 h post-transfection with DNMT3A siRNA in comparison to control si-NC cells, as 
assessed by trypan blue exclusion staining. Results represent the mean value of two independent 
experiments ± SD (ns, not significant). B) Flow cytometry data showing percentages of cells in G1, 
S and G2 phases in si-DNMT3A and si-NC RD cells at 48 h after transfection. Data are average 
values of two independent experiments. C) Western blots showing the expression levels of cyclin B, 
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and cyclin D1 in cells transfected with si-DNMT3A or si-NC for 48 h. Tubulin was used as loading 
control. Representative of two different assays. 
 
Furthermore, DNMT3A silenced RD cells did not exhibit a change in their morphology, on 
the contrary, they showed the typical round shape, as well as si-NC cells (Figure 35A). 
However, the expression of specific muscle markers was evaluated by western blot 
experiments. As expected, MYOD1, Myogenin and MyHC protein levels did not increase 
in si-DNMT3A transfected RD cells in comparison to si-NC samples, both at 72 h and 144 
h after transfection (Figure 35B), whilst low levels of DNMT3A protein has been 
observed. Altogether, these data suggest that, despite the up-regulation of both the 
enzymes in RMS tumour samples, DNMT3B has a specific role in the tumorigenesis of 
this malignancy and acts as an oncogene, whilst the functional importance of DNMT3A is 
to be clarified. 
 
 
Figure 35: DNMT3A depletion does not reactivate myogenic differentiation in RD cells. A) 
Cellular morphology of si-NC and siDNMT3A RD cells was analysed under light microscope at 
20x magnification at 72 and 144 h after siRNA transfection. B) Western blots showing the down-
regulation of DNMT3A and the expression levels of MYOD1, Myogenin and MyHC in RD cells 
transfected with si-DNMT3A or si-NC. Tubulin was used as loading control. Representative of two 
different assays. 
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DNMT3B knock-down sensitizes ERMS cell line to radiation 
We assessed whether dysfunction of DNMT3B might sensitize ERMS cells to ionizing 
radiation. For this purpose, RD cells were transfected with si-DNMT3A, si-DNMT3B or 
si-NC for 48 h and then irradiated with a single dose of 4 Gy. Twenty-four h after 
irradiation (IR) we analysed the survival rates of si-DNMT3A and si-DNMT3B cells 
compared to si-NC cells, by using trypan blue dye exclusion test. As shown in Figure 36A 
IR alone was able to slow down cell proliferation and, interestingly, DNMT3B depletion 
increased growth arrest (0.6-fold), suggesting that DNMT3B knock-down enhanced 
cellular radiosensitivity. On the contrary, cells growth was not perturbed by DNMT3A 
silencing in combination with IR, this assessing a specific role of DNMT3B in the DNA 
damage response. To further determine whether DNMT3B knock-down alters cell cycle 
distribution after IR, flow cytometry analysis was performed. Twenty-four h after 
irradiation an increase in the G2 population occurred in all the sample (G2: si-NC, 30.57% 
vs. 9.61%; si-DNMT3A, 27.51% vs. 8.42%, si-DNMT3B, 14.36% vs. 3.9%) rather than in 
si-DNMT3B cells, which exhibited an increased G1 phase in respect to both control and si-
DNMT3A transfected samples (G1: si-NC, 60.58%; si-DNMT3A, 58.07%; si-DNMT3B, 
79.04%) (Figure 36B). This result is line with the G1 cell cycle arrest reported above. 
Immunoblotting assay performed after irradiation, revealed a strong decrease of cyclin D1 
protein levels in both si-DNMT3A and si-DNMT3B compared with si-NC cells and an 
increase of cyclin B in comparison to not irradiated cells (Figure 36C). In agreement with 
the cytofluorimetric analysis, si-DNMT3B irradiated cells exhibited lower levels of cyclin 
B than si-NC and si-DNMT3A irradiated cells.  
Furthermore, when allowed to grow at low density for 11 days at 24 h after irradiation, the 
ability to form colonies decreased in all the samples compared to the respective not 
irradiated cells (si-NC, 0.12-fold; si-DNMT3A, 0.13-fold; si-DNMT3B, 0.10-fold). 
Notably, irradiated si-DNMT3B cells showed a very lower ability in anchorage-dependent 
experiments, with a 0.05-fold of crystal violet absorbance compared to si-NC cells (Figure 
37).  
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Figure 36: DNMT3B knock-down radiosensitizes RD cells. RD cells 48 h post-transfection with 
si-DNMT3A, si-DNMT3B or si-NC were exposed or not to 4 Gy irradiation. A) Viability was 
assessed 24 h after IR by trypan blue exclusion staining. Results represent the mean value of two 
independent experiments ± SD (*, p<0.05; ns, not significant). B) Flow cytometry data showing 
percentages of cells in G1, S and G2 phases in si-DNMT3A, si-DNMT3B or si-NC RD cells at 72h 
after transfection and 24 h after IR. Data are average values of two independent experiments. C) 
Western blot showing the expression levels of cyclin B and cyclin D1 in cells transfected with si-
DNMT3A, si-DNMT3B or si-NC irradiated or not with 4 Gy. Tubulin was used as loading control.  
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Figure 37: DNMT3B depletion impairs clonogenic ability of RD cells after irradiation. RD 
cells, transfected with si-DNMT3A, si-DNMT3B or si-NC for 48 h, were exposed or not to 4 Gy 
radiation treatment. Twenty-four h after IR, cells were seeded at low concentration for colony 
assays. Pictures are representative of two independent experiments, each performed in triplicate. 
Colony forming efficiency was calculated by crystal violet absorbance (***, p<0.001 vs. si-NC/0 
Gy; §§§, p< 0.001 vs. si-NC/4 Gy). 
 
Based on these results, we hypothesized that restoration of DNMT3B expression might 
increase IR-induced DNA damage. To verify this supposition, we determined whether 
DNMT3B knock-down affected IR-induced phosphorylation of H2AX (γ-H2AX), which is 
a marker of double-strand breaks (DSBs). At 24 h after irradiation a strong increase in the 
expression levels of γ-H2AX was observed in RD cells transfected with si-DNMT3B 
compared to si-DNMT3A and control cells (Figure 38A), suggesting that silencing of 
DNMT3B amplify DNA damage in RD cells. To evaluate if DNMT3B depletion was able 
to block the DNA repair machinery, we analysed the modulation of specific markers after 
IR, by using western blot. Figure 38B showed the decreased expression of Caveolin 1 
(Cav-1), ATM (ataxia-telangiectasia mutated), DNA-PKcs (DNA-dependent protein kinase, 
catalytic subunit), and RAD51, whose activation is linked to the non-homologous end 
joining (NHEJ) and the homologous recombination (HR) pathways (Maier et al., 2016), 
only in si-DNMT3B RD cells 24 h after irradiation, compared to both si-DNMT3A and si-
NC cells. Altogether, these data suggest that DNMT3B is an upstream component of DNA 
damage signalling pathway and that silencing of this enzyme is a crucial step in the 
inhibition of DNA damage/repair, this leading to radiosensitization of ERMS cells. 
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Figure 38: DNMT3B depletion impairs the DNA damage repair in RD cells. A) Western blot 
showing the phosphorylated H2AX levels in si-DNMT3A, si-DNMT3B and si-NC RD cells at 72 h 
post-transfection exposed or not to 4 Gy radiation treatment. Tubulin was used as loading control. 
Representative of two different assays. B) Immunoblotting with specific antibodies for indicated 
proteins of DNA repair signalling. Tubulin was used as loading control. Representative of two 
independent experiments.  
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DISCUSSION 
 
 
Abnormal DNA methylation can lead to carcinogenesis, affecting cancer cell phenotype. 
Indeed hypermethylation, an epigenetic mechanism resulting in transcriptional silencing of 
tumour suppressor genes, has been frequently observed in many human cancers (Esteller, 
2005; Kazanets et al., 2016; Meng et al., 2015). Rhabdomyosarcoma (RMS), the most 
common soft tissue sarcoma in children, representing for about 5% of malignant paediatric 
tumours, includes two main histological subtypes, alveolar RMS (ARMS) and embryonal 
RMS (ERMS), characterised by particular genetic alterations and different outcome 
(Parham and Barr, 2013). Aberrant methylation of CpG-islands at the promoter regions of 
different genes has also been observed in RMS (Mahoney et al., 2012; Sun et al., 2015). 
In the current study, we found an aberrant expression of DNA methyltransferase (DNMT) 
1, 3A and 3B in both ARMS and ERMS primary tumours and cell lines. In particular, our 
data show for the first time that DNMT3B transcripts are over-expressed in RMS tumours 
compared to normal skeleton muscle (NSM), suggesting that high levels of this enzyme are 
important molecular features of RMS. Our results indicate that the inhibition of DNMT3B 
expression by RNA interference impaires the in vitro tumour-promoting potential of 
ERMS cells by significantly reducing cell proliferation, migration and colony-forming 
ability. We observed altered levels of proteins involved in the cell cycle control, consistent 
with the marked cellular growth arrest at G1/S-phase transition, suggesting a key role of 
DNMT3B in sustaining RMS cell progression. Indeed, DNMT3B-mediated arrest 
correlates with the reduced expression of different cyclins (Cyclin B1, Cyclin D1 and 
Cyclin E2) and the block of the pRB/E2F1 pathway by inducing de-phosphorylation of RB 
tumour suppressor. E2F1 transcription factor plays a crucial role in the cell cycle 
progression (especially in the G1/S transition) and its deregulation has been reported in 
many human cancers (Bell and Ryan, 2004). Hypophosphorylated RB represents the active 
form of the protein that binds and inhibits E2F1, this preventing its nuclear translocation 
and blocking its ability to recruit the basic transcriptional machinery necessary for the 
activation of genes that are important in cell cycle progression (Dick and Rubin, 2013; 
Flemington et al., 1993; Helin et al., 1993). In accordance with the inhibition of cell 
proliferation, we observed a significant increase of the checkpoint regulators p21 and p27, 
72 
 
whose up-regulation might be directly related to a promoter demethylation and a 
concomitant re-expression upon DNMT3B depletion. Interestingly, despite the efficient 
growth inhibition induced by DNMT3B knock-down, flow cytometry analysis revealed 
that silencing of the enzyme does not affect apoptosis, as confirmed at molecular levels by 
cleaved PARP and Bcl-xL expression levels, but leads to the restoration of the myogenic 
fate in ERMS cell lines.  
We found that DNMT3B down-regulation is able to activate muscle-regulatory factors 
(MRFs) and myomiRs in RD and TE671 cells, two human in vitro models of ERMS. In 
particular, normalization of DNMT3B expression promotes myogenesis as shown by the 
marked up-regulation of MYOD1, followed by Myogenin and myomiR miR-133a and 
miR-206 expression, as well as by changes in the cell morphology, from round shape to 
more elongated cellular bodies. Preliminary results indicate that DNMT3B in vitro down-
regulation does not affect ARMS phenotype and does not sustain differentiation program. 
MYOD1, a master regulator of myogenesis, is expressed in proliferating myoblast and is 
able to activates the terminal differentiation program, by directly promoting the expression 
of miR-206 and many other genes involved in myogenesis (Buckingham and Rigby, 2014; 
Koutalianos et al., 2015). Several studies have suggested that transcriptional repression by 
hypermethylation of both DNA and histones at the enhancer/promoter regions of myogenic 
factors and cofactors is a potential mechanism to promote tumour formation and 
progression as well as to impair terminal differentiation in RMS (Brunk et al., 1996; 
Ciarapica et al., 2014; Keller and Guttridge, 2013; MacQuarrie et al., 2013). Human 
MYOD1 gene is located at 11p15 (Scrable et al., 1990), a chromosomal region containing 
the IGF2 and H19 genes regulated by parental imprinting (Nordin et al., 2014), whose 
expression has been found to be altered (over-expression of IGF2 and down-regulation of 
H19) in a subset of ERMS tumours (Casola et al., 1997). Chen and colleagues have found 
alterations of methylation levels in the upstream regions of the human MYOD1 gene in 
ERMS subtypes (Chen et al., 1998). Furthermore, RD proliferating cells show low levels 
of MYOD1, and has been demonstrated that an increased abundance of this transcription 
factor allows to switch RMS cells from an arrested phase to a differentiated state (Yang et 
al., 2009), this confirming that a controlled amount of MRFs is a fundamental condition for 
a proper skeletal muscle differentiation in ERMS cells. Therefore, the abnormal MYOD1 
methylation pattern observed in RMS might be due to a generalized deregulation of the 
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11p15 imprinted region. In this regard, epigenetic deregulation observed in RMS might be 
directly due to DNMT3B over-expression, since this enzyme is responsible of de novo 
DNA methylation patterns. Interestingly, DNMT3B silencing was maintained at 144 h 
after siRNA-transfection and determined long-term changes in ERMS cell phenotype, as 
assessed by the elevated levels of MyHC protein, which is specifically related to 
committed muscle cells. Moreover, we supposed that DNMT3B is a downstream effector 
of MEK/ERK signalling pathway, since we observed the decrease of DNMT3B protein 
levels upon treatment with the MEK1/2 inhibitor U0126. Protein kinase cascade that leads 
to MAPKs activation, mediates specific responses, including proliferation, differentiation 
and apoptosis (Pang et al., 1995; Robinson and Cobb, 1997). As has been previously 
demonstrated, MEK/ERK signalling disruption affects tumour growth and reactivates 
myogenesis in ERMS cells (Marampon et al., 2006; Mauro et al., 2002). Thus, the 
concomitant MEK/ERK inhibition and DNMT3B down-regulation suggest that abrogation 
of the enzyme is an essential step for reverting RMS cancer phenotype towards skeletal 
muscle differentiation, by reducing the expression of proliferative markers and up-
regulating myogenic genes. In addition, DNMT3B knock-down induced a sustained 
activation of p38 kinase, which has been reported to promote myogenesis and to maintain 
myogenic-related morphology in ERMS cells (Marampon et al., 2006; Mauro et al., 2002).  
In contrast to DNMT3B, DNMT3A silencing does not reactivate myogenic differentiation 
in ERMS cells, but induces only a mild increase in G2 phase with a concomitant reduction 
in S phase of the cell cycle. Further analysis will be required to better understanding the 
specific role of DNMT3A in RMS development and progression, since this enzyme is 
overexpressed in all the analysed RMS primary tumour samples in comparison to NSM. 
Several studies have shown different roles for DNMT3A and DNMT3B in mammalian 
development: imprinted loci during gametogenesis (Kaneda et al., 2004) and major 
satellite repeats of the pericentromeric region are preferentially methylated by DNMT3A, 
whilst minor satellite repeats are methylated by DNMT3B (Chen et al., 2003). Oka et al. 
demonstrated that Fgf-1 is preferentially methylated by DNMT3A but not by DNMT3B 
(Oka et al., 2006). In addition, Linhart and colleagues found that DNMT3B but not 
DNMT3A is able to promotes in vivo tumorigenesis, by increasing the number of intestinal 
adenomas in mice overespressing DNMT3A or DNMT3B genes (Linhart et al., 2007).  
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Recently, microRNAs (miRNAs), an emerging class of epigenetic regulators which 
regulate gene expression at the post-transcriptional level (Esteller, 2011), have been 
demonstrated to function as oncogenes or tumour suppressors (Esquela-Kerscher and Slack, 
2006; Medina and Slack, 2008), playing a crucial role in tumorigenesis, including RMS 
(Rota et al., 2011). Ectopic expression of miR-29 family members has been described in 
several human tumour types, such as hepatocellular carcinoma, nasopharyngeal 
carcinomas, breast cancer and different hematologic malignancies (Amodio et al., 2015; 
Cittelly et al., 2013; Sengupta et al., 2008; Xiong et al., 2009). The miR-29 family consists 
of miR-29a, miR-29b and miR-29c (Dostie et al., 2003; Lagos-Quintana, 2001; Lagos-
Quintana et al., 2002) which share regulatory capacity. Deregulation of miR-29b has 
already been observed in RMS, having a role in skeletal muscle differentiation (Wang et al., 
2008a). Here we found a strong down-regulation of both miR-29a and miR-29c in 14 RMS 
tumour samples in comparison to NSM, in agreement with the tumour suppressor activity 
described in other human cancers. In silico analysis followed by Q-PCR and western blot 
experiments showed that the restoration of miR-29a and miR-29c expression markedly 
reduced DNMT3B mRNA and protein levels in RD cells. Furthermore, miR-29a/miR-29c-
transfected cells reduced cell proliferation and cell migration. We also observed changes in 
the cell cycle distribution with growth arrest at G1 phase, in accordance with the 
alterations described in si-DNMT3B RD cells. These results suggest that decreased 
expression of miR-29a/miR-29c in RMS plays a crucial role in DNMT3B up-regulation, 
this promoting its oncogenic activity. In agreement with this hypothesis, previous studies 
have described that miR-29 family members target DNMT transcripts in different cell 
systems, including lung cancer, hepatocytes and acute myeloid leukemia cells (Cicchini et 
al., 2015; Fabbri et al., 2007; Garzon et al., 2009; Yan et al., 2015). Epigenetic factors 
could also affect miRNA expression, as assessed by recent studies showing miRNA 
transcriptional repression by CpG island hypermethylation in cancer cells (Lehmann et al., 
2008; Lujambio et al., 2007; Saito et al., 2006). Notably, some miRNAs, like miR-148a 
and miR-199a, target DNMT mRNAs and are themselves regulated by methylation in 
cancer cells, this generating feedback regulatory loops that tightly connect miRNAs and 
DNA methylation pathway (Chen et al., 2014; Li et al., 2014). Further analysis will be 
needed to elucidate whether in RMS is present this regulatory loop between miR-29a/miR-
29c and DNMT3B. 
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Finally, our data underline the role of DNMT3B silencing in potentiating the effects of 
radiotherapy. Indeed, depletion of DNMT3B enhances radiosensitivity of ERMS cell lines, 
as demonstrated by the reduced growth rate confirmed by the alteration in cell cycle 
progression. In addition, clonogenic assay reveales a survival reduction of about 95% in si-
DNMT3B irradiated cells in comparison to si-NC cells. Since IR induces double-strand 
break (DSBs) and radiosensitivity is mediated by inhibition of the NHEJ and the HR DNA 
repair pathways (Maier et al., 2016), we analysed the mechanism of radiosensitization in 
RD cells. At 24 h after irradiation with 4 Gy we observed that only DNMT3B silencing 
causes a marked increased in the phosphorylation levels of the H2AX histone variant (γ-
H2AX), which is a marker of the DNA DSBs (Kuo and Yang, 2008), suggesting that 
DNMT3B enzyme is an upstream component of the DNA damage signalling pathway. 
Moreover, we showed that DNMT3B knock-down abrogates the IR-induced Cav-1, ATM, 
DNA-PKcs and RAD51 expression levels. Cav-1 plays a crucial role in both HR and NHEJ 
DNA damage response (DDR), activating downstream molecules in the signalling cascade 
(Zhu et al., 2010). ATM and DNA-PKcs, members of the phosphatidylinositol 3-kinase-
related kinase (PIKK) family, are the primary transducers of DSB-induced signalling. 
DNA-PKcs is itself a target of ATM, which is the master regulator of DDR through the 
detection of DSBs (Callén et al., 2009). DNA-PKcs is essential for NHEJ (Smith and 
Jackson, 1999), whilst RAD51 plays a major role in HR pathway (Alshareeda et al., 2016). 
Altogether, our data demonstrate that inhibition of DNMT3B is a crucial mechanism to 
prevent DNA damage response, which in turn leads to tumour cell radiosensitivity.  
Based on the present results, DNMT3B may represent a new important molecule 
explaining the molecular mechanisms by which ERMS cells fail to activate/complete the 
skeletal muscle differentiation program. Previous reports have demonstrated that 
epigenetic modifications, comprehending both acetylation and methylation in the 5’-
flanking regulatory regions, play a crucial role in the regulation of progressional changes in 
transcription necessary for muscle differentiation (Hupkes et al., 2011; Laker and Ryall, 
2016; Lucarelli et al., 2001). DNMT3B might act in two different way: directly by 
hypermethylating DNA or by cooperating with other factors able to modify chromatin, 
such as histone deacetylases (HDACs) and Polycomb-group (PcG) proteins (Jin et al., 
2009; Purkait et al., 2016). In this regard, preliminary results obtained in our laboratory 
indicate that DNMT3B and the histone methyltransferase EZH2 (Enhancer of zeste 
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homolog 2), the catalytic subunit of the Polycomb Repressor Complex 2 (PRC2), are able 
to interact in both RD and TE671 ERMS cells. Bisulfite sequencing and chromatin 
immunoprecipitation (ChIP) assays will be carry out in our laboratory to fully characterise 
the possible epigenetic modifications at enhancer/promoter regions associated with 
myogenic markers expression in si-DNMT3B RMS cells in comparison to control mocked 
samples. Preliminary ChIP assay revealed an increased binding of MYOD1 to E-box 2 on 
the promoter of miR-206 in si-DNMT3B RD cells. 
Furthermore, recent findings have shown that DNMT3 enzymes can repress transcription 
in a methylation-independent manner (Haney et al., 2015), since their capacity to bind with 
their plant homeodomain-like motif at N-terminal domain (Aasland et al., 1995) silencer 
complexes comprehending MBD (Methyl CpG binding) proteins or specific transcriptional 
repressors (Buck-Koehntop and Defossez, 2013; Hervouet et al., 2009; Oikawa et al., 2011; 
Palacios et al., 2010). So, the molecular mechanisms of DNMT3B-mediated transcriptional 
silencing at muscle-gene regulatory regions in RMS could be due to its potential repressor 
activity. The finding that DNMT3B knocking down induces cell cycle arrest and commits 
ERMS cells to myogenesis suggests that this strategy has a therapeutic potential in ERMS 
tumours, this outlining the importance to test the antitumour effects of this DNMT3B 
siRNA molecules in mouse xenograft models. 
In recent years has emerged that demethylating agents or HDAC inhibitors have pro-
differentiative effects in RMS cells by up-regulating the expression levels of different 
muscle-specific coding genes and miRNAs. In a previous work we demonstrated that 5-
aza-dC DNA demethylating agents is able to up-regulate miR-378a-3p (down-regulated in 
RMS tumour samples), inducing apoptosis, decrease in cell migration, G2-cell cycle arrest 
and myogenic differentiation (Megiorni et al., 2014). Furthermore, Kim et al. previously 
reported that several DNMT inhibitors radiosensitize human cancer cells by suppressing 
DNA repair activity (Kim et al., 2012). Currently, 5-aza and 5-aza-dC DNA 
demethylanting agents have been approved by US FDA for the treatment of 
haematopoietic malignancies (Fahy et al., 2012; Flis et al., 2014; Jones et al., 2016) but, 
their efficacy in the treatment of human solid tumours is still controversial (Bauman et al., 
2012). In addition, it is important to note that the mechanism of action of 5‑aza and 5‑aza-
dC remains to be fully understood (Stresemann and Lyko, 2008) and that long-term 
exposure induces high levels of toxicity (Karahoca and Momparler, 2013). Reduced 
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representation bisulfite sequencing (RRBS) experiments are underway in our laboratory to 
characterise the genome-wide methylation profiles in si-DNMT3B vs. si-NC cells in order 
to provide a deeper insight into the RMS tumorigenesis, and to identify new potential 
targets for the development of more effective and less toxic epigenetic therapies. Indeed, 
non-nucleoside compounds, which are independent of replication for their incorporation 
into DNA, or other molecules with a high biochemical selectivity towards individual 
human DNMT enzymes might lead to promising anticancer therapies (Graça et al., 2014; 
Sandhu et al., 2012), and this also in RMS.  
In conclusion, this study describes for the first time the over-expression of DNMT3B gene 
in RMS primary tumour and cell lines, suggesting that an aberrant transcriptional control 
mediated by this de novo DNMT is a key event in RMS development and progression. Our 
findings also outline the potential clinical application of DNMT3B inhibition in cancer 
treatment. DNMT3B target therapies may represent a novel clinical approach, effective not 
only in impairing tumour growth but also in reactivating myogenic program and increasing 
the sensitivity to radiotherapy, especially in ERMS subtypes.  
 
 
Part of the results of this research project have been published in the international journal 
Oncotarget: Megiorni F, Camero S, Ceccarelli S, McDowell HP, Mannarino O, Marampon 
F, Pizer B, Shukla R, Pizzuti A, Marchese C, Clerico A, Dominici C. (2016) DNMT3B in 
vitro knocking-down is able to reverse the embryonic rhabdomyosarcoma cell phenotype 
through inhibition of proliferation and induction of myogenic differentiation. Oncotarget. 
Nov 29; 7 (48): 79342-79356. 
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